Government eProcurement System

Government eProcurement System

Tender Details

Date : 19-Aug-2026 04:23 PM

Print

Basic Details

Organisation Chain	Council of Scientific and Industrial Research||NAL Bengaluru - CSIR||Purchase-NAL - CSIR		
Tender Reference Number	NAL/PUR/MED/048/26		
Tender ID	2026_CSIR_288157_1	**Withdrawal Allowed**	Yes
Tender Type	Open Tender	**Form of contract**	Supply
Tender Category	Goods	**No. of Covers**	2
General Technical Evaluation Allowed	No	**ItemWise Technical Evaluation Allowed**	No
Payment Mode	Offline	**Is Multi Currency Allowed For BOQ**	No
Is Multi Currency Allowed For Fee	No	**Allow Two Stage Bidding**	No

Payment Instruments

Offline

S.No	Instrument Type
1	Demand Draft
2	Bank Guarantee

Cover Details, No. Of Covers - 2

Cover No	Cover	Document Type	Description
1	Fee/PreQual/Technical	.pdf	EARNEST MONEY DEPOSIT AS PER THE TENDER DOCUMENT
		.pdf	DOCUMENTS COMPRISING THE E-BID (TECHNICAL BID) AS PER CLAUSE 1.9 OF THE TENDER DOCUMENT
		.pdf	Submission of Integrity Pact on Letter Head duly signed and stamped as per Annexure-H of the Tender
2	Finance	.xls	PRICE BID AS PER BOQ
		.pdf	BID FORM AS PER ANNEXURE-D OF THE TENDER DOCUMENT

Tender Fee Details, [Total Fee in ₹ * - 0.00]

Tender Fee in ₹	0.00		
Fee Payable To	Nil	**Fee Payable At**	Nil
Tender Fee Exemption Allowed	No		

EMD Fee Details

EMD Amount in ₹	5,00,000	**EMD Exemption Allowed**	No
EMD Fee Type	fixed	**EMD Percentage**	NA
EMD Payable To	THE DIRECTOR	**EMD Payable At**	BENGALURU

Click to view modification history

Work /Item(s)

Title	ESTABLISHMENT AND OPERATION OF SINGLE WINDOW PHARMACY MANAGEMENT SYSTEM (SWPMS)
Work Description	ESTABLISHMENT AND OPERATION OF SINGLE WINDOW PHARMACY MANAGEMENT SYSTEM (SWPMS)
Pre Qualification Details	Please refer tender documents
Independent External Monitor/Remarks	AS PER TENDER DOCUMENT
Show Tender Value in Public Domain	No

Tender Value in ₹	0.00	**Product Category**	Miscellaneous Goods	**Sub category**	NA
Contract Type	Tender	**Bid Validity(Days)**	90	**Period Of Work(Days)**	365
Location	CSIR NATIONAL AEROSPACE LABORATORIES, BENGALURU	**Pincode**	560017	**Pre Bid Meeting Place**	ICAST Division, CSIR-NAL, BENGALURU
Pre Bid Meeting Address	ICAST Division, CSIR-NAL, HAL AIRPORT ROAD, KODIHALLI, BENGALURU 560017	**Pre Bid Meeting Date**	31-Aug-2026 11:00 PM	**Bid Opening Place**	Purchase Section, CSIR NAL, Kodihalli, Bengaluru
Should Allow NDA Tender	No	**Allow Preferential Bidder**	No		
Tenderer Class	Not Applicable				

Critical Dates

Publish Date	19-Aug-2026 05:00 PM	**Bid Opening Date**	11-Sep-2026 11:00 AM
Document Download / Sale Start Date	19-Aug-2026 05:00 PM	**Document Download / Sale End Date**	10-Sep-2026 10:00 AM
Clarification Start Date	19-Aug-2026 05:00 PM	**Clarification End Date**	27-Aug-2026 04:00 PM
Bid Submission Start Date	19-Aug-2026 05:00 PM	**Bid Submission End Date**	10-Sep-2026 10:00 AM

Tender Documents

NIT Document

S.No	Document Name	Description	Document Size (in KB)
1	Tendernotice_1.pdf	Establishment and Operation of Single Window Pharmacy Management System (SWPMS)	1932.29

Work Item Documents

S.No	Document Type	Document Name	Description	Document Size (in KB)
1	BOQ	BOQ_336145.xls	PRICE BID AS PER BOQ	257.50

Auto Extension Corrigendum Properties for Tender

Iteration	No. of bids required for bid opening a tender	Tender gets extended to No. of days
1.	2	7

Bid Openers List

S.No	Bid Opener Login Id	Bid Opener Name	Certificate Name
1.	anusha.eproc@csir.res.in	Anusha Manonmani T	ANUSHA MANONMANI
2.	saurav.eproc@csir.res.in	Saurav Kumar	SAURAV KUMAR
3.	damodhar@csir.res.in	B DAMODHAR RAO	BABU RAO DAMODHAR RAO
4.	km.eproc@csir.res.in	Kala M	KALA M

GeMARPTS Details

GeMARPTS ID	1N6UODEBHSCH
Description	Establishment and Operation of Single Window Pharmacy Management System (SWPMS)
Report Initiated On	19-Aug-2026
Valid Until	18-Sep-2026

Tender Properties

Auto Tendering Process allowed	No	**Show Technical bid status**	Yes
Show Finance bid status	Yes	**Stage to disclose Bid Details in Public Domain**	Technical Bid Opening
BoQ Comparative Chart model	Normal	**BoQ Compartive chart decimal places**	2
BoQ Comparative Chart Rank Type	L	**Form Based BoQ**	No

TIA Undertaking

S.No	Undertaking to Order	Tender complying with Order	Reason for non compliance of Order
1	TIA UNDERTAKING GEM	Agree	
2	PPP-MII Order 2017	Agree	
3	MSEs Order 2012	Agree	

Tender Inviting Authority	
Name	THE DIRECTOR
Address	CSIR NATIONAL AEROSPACE LABORATORIES, HAL AIRPORT ROAD, KODIHALLI, BENGALURU

Tender Creator Details	
Created By	Anusha Manonmani T
Designation	Junior Secretariat Assistant
Created Date	19-Aug-2026 03:49 PM

TENDER NO: NAL/PUR/MED/048/26 **Date: 18-Aug-2026**

TENDER DOCUMENT

FOR

ESTABLISHMENT AND OPERATION OF SINGLE WINDOW PHARMACY MANAGEMENT SYSTEM (SWPMS)

COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
NATIONAL AEROSPACE LABORATORIES
PB NO.1779, HAL AIRPORT ROAD, BENGALURU – 560 017
KARNATAKA-INDIA

Council of Scientific and Industrial Research
National Aerospace Laboratories
PB No.1779, HAL Airport Road, Bengaluru – 560 017, Karnataka-India
Tel #: 00 91 80 25086040/6041
Email: purchasek@nal.res.in
Website: **www.nal.res.in**

Invitation for Bids / Notice Inviting E-TenderD

CSIR-National Aerospace Laboratories (CSIR-NAL), Bengaluru, India, is a premier research institution of the Council of Scientific and Industrial Research (CSIR), an autonomous organization of the Ministry of Science & Technology, Government of India, New Delhi. CSIR-NAL is a science-driven research, development, and consulting organization renowned internationally for its excellence in aerospace engineering and scientific research.

The Director, CSIR-NAL invites electronic Bids (e-Bids) from reputed and eligible Pharmacy Service Providers, Registered Retail Pharmacy Chains, or Integrated Pharmaceutical Enterprises for the Establishment and Operation of a Single Window Pharmacy Management System (SWPMS) at the CSIR-NAL Health Centre.

The Director, CSIR-NAL invites bids for outsourcing the following services essential for the Institute's daily operations. The detailed scope of work is annexed herewith.

Sr. No.	Tender No.	Brief Description of item(s)	Quantity	Type of Bid	Mode of Procurement
1	NAL/PUR/MED/048/26	Establishment and Operation of Single Window Pharmacy Management System (SWPMS)	Details as per BoQ	Single Stage Two Bid System	Open Tender [CPP Portal-Online]

1. **E-Bids are invited** through the electronic tendering process and the Tender Document can be downloaded from the e-Tender Central Public Procurement Portal (CPPP) of Government of India, https://etenders.gov.in. A copy of the Tender Document is also available on CSIR-NAL website, www.nal.res.in. **The submission of e-Bids will be only through the e-Tender portal https://etenders.gov.in. BIDS WILL NOT BE ACCEPTED IN ANY OTHER FORM.**

2. All requests for information or clarifications regarding this bid document shall be submitted exclusively through the CPP Portal within the prescribed clarification/query period. ***No queries or requests for clarification sent directly to the office by email shall be entertained, except those specifically invited for the purpose of the pre-bid conference.***

3. The prospective bidders should adhere to due dates specified in Tender Details Screen corresponding to this tender on E-Tender portal https://etenders.gov.in.

4. **Pre-Bid Conference (PBC):** A Pre-Bid Conference (PBC) shall be held on the date, time, and venue specified in the tender document. Bidders are encouraged to attend the Pre-Bid Conference in person at the venue specified in the tender document. However, bidders who are unable to attend physically may participate through the online meeting link.

Pre-Bid Conference Details

Date & Time	31-Aug-2026, 11:00 AM (IST)
Venue	ICAST, CSIR-NAL, HAL Airport Rod, Kodihalli, Bengaluru – 560 017
Online Link (if bidder cannot attend offline)	Link will be available on CSIR-NAL website.

NOTE: Attendance at the Pre-Bid Conference is mandatory for all prospective bidders. Bids submitted by firms who fail to attend this conference are liable to be rejected during initial scrutiny.

5. **Bid Security (BS)/Earnest Money Deposit (EMD):** The Bid prepared by the Bidder shall include the following:
   a) The amount of **Bid Security (BS)/Earnest Money Deposit (EMD)** shall be **Rs.5,00,000/- (Rupees Five Lakh only)**.
   b) The **BS/EMD** shall be furnished in the form of a **Bank Guarantee (BG)/Demand Draft (DD)** drawn in favour of **"The Director, National Aerospace Laboratories, Bengaluru"**. The original BS/EMD instrument, clearly indicating the **Tender No. and details of the tender**, shall be delivered to the address given below on or before the prescribed **bid submission date and time** specified in the **Date Sheet**. Failure to submit the original BS/EMD instrument within the stipulated time shall render the bid liable for **summary rejection**.
   Address for submission of Original BS/EMD:
   The Director
   CSIR-National Aeospace Laboratories
   HAL Airport Road, Kodihalli, Bengaluru-560017, Karnataka-India
   c) For further details, bidders may refer to **Clause No. 1.13 of the Tender Document**.

6. **Bid Securing Declaration (BSD):** Bidders shall submit a duly filled and signed Bid Securing Declaration (BSD) in the prescribed format along with the Technical Bid. The BSD shall be submitted in the name of "The Director, CSIR-National Aerospace Laboratories, Bengaluru". The format of the Bid Securing Declaration is enclosed as an Annexure to this tender document. Bids not accompanied by the duly signed BSD are liable to be rejected.

7. Performance Security (PS): The amount of **Performance Security (PS)** shall be **Rs.25,00,000/- (Rupees Twenty five Lakh only)**.

8. **Non-Disclosure Agreement (NDA):** The successful bidder shall submit a Non-Disclosure Agreement (NDA) in the prescribed format after award of the contract and before commencement of contract. The NDA shall cover all confidential information, data, documents, records, and other information made available by CSIR-NAL during the course of contract execution.

The **Non-Disclosure Agreement (NDA)** shall be executed on a **Rs.500/- non-judicial stamp paper** and duly signed by the authorised signatory of the bidder. Compliance with the terms and conditions of the NDA shall form an integral part of the contractual obligations under the Contract. The format of NDA will be shared on award of contract.

9. IMPORTANT NOTE: For MSME/ Start-up India/ MII Bidders

The provisions relating to the Government of India's public procurement purchase preference policies, including but not limited to MSME, Start-Up India, Make in India, or any other policy presently in force, are outlined in the relevant clauses of this tender document. Any bidder seeking to claim exemption, preference, or benefit under such policies must submit, along with its bid, all relevant documents, certificates, and evidence required to establish eligibility for such benefits. The bidder must explicitly identify the specific policy provisions invoked and the nature of the benefit claimed, demonstrating compliance with the eligibility criteria detailed under the applicable policy. No benefits, preferences, or concessions beyond the scope of the stated policy or the bidder's entitlement thereunder shall be considered. If a bidder fails to claim such benefits and/or fails to submit requisite documentation supporting such claim at the time of bid submission, no further opportunity will be provided to the bidder to furnish such documents or revise the claim during any subsequent stage of the bidding process, and the claim shall be deemed forfeited and shall not be entertained thereafter.

10. The bids of those bidders failing to comply the following clauses will be summarily rejected.

(a) The bidders proposing to supply finished products directly/indirectly from Bidders of Countries sharing the land border with India should submit copy of registration done with the Ministry of Home Affairs and Ministry of External Affairs.

(b) If the products supplied are not from Bidders of Countries sharing Land border with India, the Bidders should enclose a declaration

(c) The debarment of a Bidder/Vendor in this tender, if any, is reciprocal of that Principal's Country, if it is Import.

11. This tender document has been prepared in alignment with the strategic objectives of CSIR-NAL's operations. Any terms, conditions, or clauses herein that appear irrelevant to the specific bidding context (e.g., online or offline mode or not relevant to the services being sought) may be ignored. Similarly, should any clause or term be interpreted as unduly restrictive, bidders are requested to bring it to the attention of the undersigned.

12. Vide CVC directions, the names and contact details of the **Independent External Monitors (IEMs)** are as below:

Shri Jagadip Narayan Singh, IAS (Retd.) C-54, Bharatendu Harischandra Marg, Anand Vihar, Delhi – 110 092 **Email:** jagadipsingh@yahoo.com	Shri Arun Kumar Gupta, Ex-CMS, SCI 68B, Nandanvan CHS Sector 17 Nerul, Navi Mumbai – 400 706 **Email:** guptaarun55@rediffmail.com

13. The Director, CSIR-National Aerospace Laboratories (NAL), Bengaluru, India reserves the right to accept or reject any or all tenders / offers either in part or in full or to annul the tender process at any stage without assigning any reasons there for.

Sd/-
Stores & Purchase Officer

CHAPTER 1 - INSTRUCTIONS TO BIDDERS (ITB) & GENERAL CONDITIONS OF CONTRACT (GCC)

INSTRUCTIONS TO BIDDERS (ITB)

CHAPTER-1
INSTRUCTION TO BIDDERS AND
GENERAL CONDITIONS OF THE CONTRACT

A. Introduction

Instructions to bidder are broad guidelines to be followed while formulating the bid and its submission to the Purchaser. It also describes the methodology for opening and evaluation of bids and consequent award of contract.

1.1 Eligible Bidders

1.1.1. This Invitation for Bids is open to all eligible and qualified bidders having valid Medical/Pharmacy license in their own name.

1.1.2. Bidders who fulfil the **Eligibility Criteria** will be considered for **Technical Evaluation of bids.**

1.1.3. The bidders who have been temporarily suspended or removed from the list of registered suppliers by the purchaser or banned from Ministry/country wide procurement **shall be ineligible** for participation in the bidding process.

1.2 Cost of Bidding

1.2.1 The Bidder shall bear all costs associated with the preparation and submission of its bid, and "the Purchaser", will in no case be responsible or liable for these costs, regardless of the conduct or outcome of the bidding process.

1.3 Code of Integrity

1.3.1 The bidders should sign a declaration about abiding by the Code of Integrity for Public Procurement in bid documents. In case of any transgression of this code, the bidder is not only liable to be removed from the list of registeredsuppliers, but it would be liable for other punitive actions such as cancellation of contracts, banning and blacklisting or action in Competition Commission of India, and so on.

1.3.2 Code of integrity for Public Procurement:

The Purchaser as well as bidders, suppliers, contractors, and consultants should observe the highest standard of ethics andshould not indulge in the following prohibited practices, either directly or indirectly, at any stage during the procurement process or during execution of resultant contracts:

i)	**Corrupt practice**	making offers, solicitation or acceptance of bribe, rewards or gifts or any material benefit, in exchange for an unfair advantage in the procurement process or to otherwise influence the procurement process or contract execution;
ii)	**Fraudulent practice**	any omission or misrepresentation that may mislead or attempt to mislead so that financial orother benefits may be obtained or an obligation avoided. This includes making false declaration or providing false information for participation in a tender process or to secure a contract or in execution of the contract;
iii)	**Anti-competitive practice**	any collusion, bid rigging or anti-competitive arrangement, or any other practice coming under the purview of the Competition Act, 2002, between two or more bidders, with or without the knowledge of the purchaser, that may impair the transparency, fairness and

		the progress of the procurement process orto establish bid prices at artificial, non-competitive levels;
iv)	**Coercive practice**	harming or threatening to harm, persons or their property to influence their participation in the procurement process or affect the execution of a contract;
v)	**Collusive practice**	means a scheme or arrangement between two or more bidders, with or without the knowledge of the purchaser, designed to establish bid prices at artificial, non-competitive levels.
vi)	**Conflict of interest**	participation by a bidding firm or any of its affiliates that are either involved in the consultancy contract to which this procurement is linked; or if they are part of more than one bid in the procurement;or if the bidding firm or their personnel have relationships or financial or business transactions with any official of purchaser who are directly or indirectly related to tender or execution process of contract; or improper use of information obtained by the (prospective) bidder from the purchaser with an intent to gain unfair advantage in the procurement process or for personal gain; and
vii)	**Obstructive practice**	materially impede the purchaser's investigation into allegations of one or more of the above mentioned prohibited practices either by deliberately destroying, falsifying, altering; or by concealing of evidence material to the investigation; or by making false statements to investigators and/or by threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or by impeding the purchaser's Entity's rights of audit or access to information;

1.3.3 Obligations for Proactive disclosures

(i) The Purchaser as well as bidders, suppliers, contractors and consultants, are obliged under Code of Integrity for Public Procurement to ***suo moto*** proactively declare any conflicts of interest (coming under the definition mentioned above – pre-existing or as and as soon as these arise at any stage) in any procurement process or execution of contract. Failure to do so would amount to violation of this code of integrity; and

(ii) The bidder must declare, whether asked or not in a bid document, any previous transgressions of such a code of integrity with any entity in any country during the last 3 (three) years or of being debarred by any other Procuring Entity.Failure to do so would amount to violation of this code of integrity;

(iii) To encourage voluntary disclosures, such declarations would not mean automatic disqualification for the bidder making such declarations. The declared conflict of interest would be evaluated and mitigation steps, if possible, takenby the purchaser. Similarly, voluntary reporting of previous transgressions of Code of Integrity elsewhere may be evaluated and barring cases of various grades of debarment, an alert watch may be kept on the bidder's actions in thetender and subsequent contract.

1.3.4 Punitive Provisions

Without prejudice to and in addition to the rights of the Purchaser to other penal provisions as per the bid documents or contract, if the Purchaser comes to a conclusion that a (prospective) bidder/supplier, directly or through an agent, has violated this code of integrity in competing for the contract or in executing a contract, the purchaser may take appropriate measures including one or more of the following:

(i) If his bids are under consideration in any procurement

a) Forfeiture or encashment of bid security;
b) Calling off any pre-contract negotiations; and
c) Rejection and exclusion of the bidder from the procurement process.

(ii) If a contract has already been awarded

a) Cancellation of the relevant contract and recovery of compensation for loss incurred by the purchaser;
b) Forfeiture or encashment of any other security relating to the procurement;
c) Recovery of payments including advance payments, if any, made by the purchaser along with interestthereon at the prevailing rate.

(iii) Provisions in addition to above:

a) Removal from the list of registered suppliers and banning/debarment of the bidder from participation infuture procurements of the purchaser for a period not less than one year;
b) In case of anti-competitive practices, information for further processing may be filed under a signature of the Joint Secretary level officer, with the Competition Commission of India;
c) Initiation of suitable disciplinary or criminal proceedings against any individual or staff foundresponsible.

1.3.5 The Purchaser will reject a proposal for award if it determines that the Bidder recommended for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive or coercive practices in competing for the Contract in question.

B. The Bidding Documents

1.4 **Cost of Bidding Documents**

The bidding documents are to be **downloaded Free of Cost** from CPPP website https://etenders.gov.in or CSIR-NAL's website www.nal.res.in.

1.5 **Content of Bidding Documents**

1.5.1 The Services required, bidding procedures and contract terms are prescribed in the bidding documents which should be read in conjunction. The bidding documents, apart from the Invitation for Bids / Notice Inviting.

1.5.2 The Bidder is expected to examine all instructions, forms, terms, and scope of services in the bidding documents. Failure to furnish all information required by the bidding documents or submission of a bid not substantially responsive to the bidding documents in every respect will result in rejection of its bid.

1.6 Clarification on Bidding Documents

1.6.1 All clarifications or queries pertaining to this bid document, if any, shall be submitted exclusively through the CPPP within the stipulated timelines indicated there. No direct emails or communications addressing general bid-related queries shall be sent to the office, except for queries specifically relating to PBC which may be directed only to the designated email ID provided for this purpose. Any other emails or communications received outside these channels will not be entertained.

1.6.2 **PRE-BID CONFERENCE (PBC)**

A Pre-bid Conference (PBC) will be conducted exclusively in **ONLINE** mode, in accordance with the details provided on the CPPP. All prospective bidders are strongly urged to participate. The participation link will be made available on the specified website. To facilitate the effective conduct of the PBC, interested bidders are required to submit their queries in advance via email to purchasek@nal.res.in/mkala@nal.res.in. Please note that, due to time limitations, fresh or on-the-spot queries may not be entertained during the conference. All queries received in advance will be addressed during the PBC, and the responses will form part of the official conference proceedings.

These proceedings, including any clarifications and amendments arising from the PBC, shall constitute official updates to the bidding documents. They will be binding on all prospective bidders for the purpose of bid submission. The proceedings will also be published on both the CPPP and the CSIR-NAL website for reference by all bidders. Prospective bidders are advised to review these websites after the completion of the Pre-bid Conference to ensure awareness of any changes or updates incorporated into the bidding document before preparing and submitting their bids. No queries shall be entertained after the PBC.

1.7 Amendment to Bidding Documents

1.7.1 At any time prior to the due date for submission of bids, the Purchaser may, for any reason, whether at its own initiative or in response to a clarification requested by a prospective bidder modify the Bid Document by amendment. Such amendments shall form an integral part of bid documents and it shall amount to an amendment of relevant clauses of the Bid Document.

1.7.2 All prospective bidders who have down loaded the Tender Document should surf CPPP website https://etenders.gov.in from time to time to know about the changes / modifications in the Tender Document. The changes / modifications would also be hosted on the CPPP website. All prospective bidders are expected to surf the CPPP website before formulating and submitting their bids to take cognizance of the amendments.

1.7.3 In order to allow prospective bidders reasonable time to take the amendment into account while formulating their bids, the Purchaser, at its discretion, may extend the due date for the submission of bids and host the changes on the CPPP and website of the purchaser.

1.7.4 If the bids are submitted without considering these amendments/ clarifications so issued, such bids will be rejected. Further bidder will be fully responsible for downloading of the tender document and amendments thereto if any for their completeness.

C. Preparation of bids

1.8 Language of Bid

1.8.1 The Bid prepared by the Bidder and all correspondence and documents shall be written in English language, provided that any printed literature furnished by the bidder may be written in another language but it is to be accompanied by an English translation of its pertinent passage(s) duly signed and verified as true English translation. The responsibility for the correctness of the translation will be solely and completely on the bidder and NAL shall not be responsible for any loss/likely loss due to error in translation whatsoever. In such cases, for the purpose of interpretation of the bid, the English translation shall only govern.

1.8.2 Bidder may find some of the points mentioned under ***ITB, Scope of Services, Qualification & Eligibility criteria and Terms & Conditions*** part of this bid document repetitive in nature. All points must be replied consistently in the submitted bid.

1.9 Documents Comprising the E-Bid

1.9.1 The E-bid shall comprise of the documents as per the requirement of the Tender Document listed under Documents comparing Technical Bid and Price Bid. The documents should be scanned and **uploaded in PDF format** on CPP portal only.

1.9.2 The **Techno-Commercial Unpriced Bid** prepared by the Bidder shall include the following without indicating the price inthe Bid Form.

Sr. No.	Documents
1	Earnest Money Deposit in the form of Demand Draft/Bank Guarantee
2	Bid Securing declaration
3	Bidder Information Form
4	Bid Form – without mentioning price and discount
5	Performance Statement Form
6	Bidders Undertaking
7	Eligibility Certificate, Non-Black Listing and No Relation Certificate
8	Code of Integrity
9	Solvency Certificate from Bank
10	Letter duly signed by the authorized person and stamped addressed to the Director, CSIR-NAL, Bengaluru indicating the local office and name of authorized person and his contact number at Bengaluru [Rural and Urban]
11	Copy of Consolidation License/Certificate in their name or firm directly owned by / belongs to same group of bidder Company/ firm.
12	Copy of ISO 9001 (2005 or later) Quality Management System Certification.
13	Copy of Goods & Services Tax Registration Certificate and PAN
14	Bidder's commercial terms without disclosing any price / discount elements
15	Audited Balance Sheet duly certified the chartered accountant
16	Undertaking on the Letterhead confirming submission of Performance Security
17	Integirty pact on letter head duly signed and stamped
18	Compliance/Deviation Statement

1.9 Bid Form

The bidder shall complete the Bid Form as furnished in the bidding documents. These forms must be completed without any alterations to its format and no substitutes shall be accepted. All blank spaces shall be filled in with the information requested. The Bid Form shall be submitted in accordance with the bidding documents.

1.10 Bid Prices

(i) Rates of services quoted.

(ii) Taxes shall be paid at actual at the applicable rates at the time of invoicing. Rates must be quoted exclusive of thetaxes.

(iii) Rates should be quoted FOR at NAL, Bengaluru or any other named place.

(iv) Except for the statutory charges, levies, and other receipt-based charges which are not specifically mentioned in the bid items, prices quoted by the bidder shall remain fixed during the entire period of contract and shall not be subject to variation on any account. No separate receipts shall be required for those quoted prices. A bid submitted with an adjustable price quotation will be treated as non-responsive andrejected summarily.

1.11 Documents Establishing Bidder's Eligibility and Qualifications

1.12.1 The bidder shall furnish, as part of its bid, documents establishing the bidders' eligibility to bid and its qualification to perform the contract if its bid is accepted.

1.12.2 Bidders must carefully review the entire tender document to fully understand the eligibility criteria, qualifications, and supporting documents required. All such documents shall be furnished completely and accurately to avoid summary rejection during preliminary scrutiny or subsequent bid evaluation stages.

1.12.3 The documentary evidence of the bidder's qualification to perform the contract if the bid is accepted shall establish to the purchaser's satisfaction that the bidder meets the qualification criteria listed in the bid document, if any.

1.12.4 Conditional tenders / offers shall **not** be accepted.

1.13 Bid Security (BS) / Earnest Money Deposit (EMD)

1.13.1 The Bid Security/Earnest Money Deposit (BS/EMD) shall be furnished in the form of a **Demand Draft (DD) or Bank Guarantee (BG)** in favour of **"The Director, CSIR-National Aerospace Laboratories, Bengaluru"**. Submission of BS/EMD is mandatory for all bidders, including **Micro and Small Enterprises (MSEs)/SMEs**, unless specifically exempted under the provisions of the Tender Document.

1.13.2 Bids submitted without the required BS/EMD, wherever applicable, shall be **summarily rejected**.

1.14 Period of Validity of Bids

1.14.1 Bids shall remain valid for minimum of 90 days after the date of bid opening prescribed by the Purchaser. A bid valid for a shorter period shall be rejected by the Purchaser as non-responsive and rejected summarily.

1.14.1 In exceptional circumstances, the Purchaser may solicit the Bidder's consent to an extension of the period of validity. A Bidder may refuse the request without any adverse action. A Bidder granting the request will not be required nor permitted to modify its bid.

1.15 Format and Signing of Bid

1.15.1 The bids may be submitted as Single-bid or Two-bid as specified in the ITB / NIT.

1.15.2 In case of two-bid system, the Bidder shall submit E-bid in two separate parts.

(a)	First Part	shall contain Techno-Commercial Bid/ Technical Bid comprising all documents listed relating to Documents Comprising the Bid excepting Bid form and Price Schedule Form
(b)	Second Part	Shall contain the Price-Bid comprising Bid Form and Price Schedule form.

1.15.3 The bids will either be digitally or physically signed by the Bidder or a person or persons duly authorized to bind the Bidder to the Contract. All pages of the bid, except for un-amended printed literature, shall be initialled by the person or persons signing the bid.

1.15.4 Any interlineations, erasures or overwriting shall be valid only if they are initialled by the person or persons signing the bid.

D. Submission of E-Bids

1.16 Submission of E-Bids

1.16.1 Bids shall be submitted online only at CPPP website https://etenders.gov.in. **Manual/ Offline / Email bids shall not be accepted under any circumstances.**

1.16.2 Bidders must follow guidelines or directions of NIC CPPP website for properly uploading the bids and CSIR-NAL will not be responsible for bids which could not be submitted do to CPPP

technical issues etc. Just like the bidder, purchaser is also a user of CPPP and any technical issue related to bid submission must only be raised to them.

1.16.3 Bidders are advised to visit CPPP website https://etenders.gov.in regularly till closing date of submission of bid, for any corrigendum and to keep themselves updated, for any changes/modifications in the Tender Enquiry Document.

1.16.4 Purchaser shall receive the bids online through CPPP portal only. The e-Tender portal shall automatically stop accepting bids after the scheduled date and time specified in the Tender Document. Partially submitted bids shall be treated as invalid and shall not be processed.

1.17 Due Date for Submission of E-Bids

1.17.2. Bidders are advised to upload and submit their E-bids timely within due date for submission of E-Bids in view of the electronic process so as to avoid last minute issues.

1.17.3 The Purchaser may, at its discretion, extend the due date for submission of E-bids by amending the tender documents in accordance with Clause relating to Amendment of Bidding Documents in which case all rights and obligations of the Purchaser and Bidders previously subject to the due date will thereafter be subject to the due date as extended.

1.18 Late Submission of E-Bids

1.18.1 Bidders must note that the e-tender portal shall not permit uploading of bids after the scheduled time of submission.

1.19 Withdrawal, substitution and Modification of Bids

1.19.1 The bidder may withdraw, correct or modify their digitally signed bid after submission prior to the deadline for submission of bids, through provisions of e-tendering portal.

1.19.2 The bidder is not allowed to modify or withdraw bid after due date for submission of bids.

E. Opening and Evaluation of E-Bids

1.20 **Opening of E-Bids by the Purchaser**

1.20.1 The E-bids shall be opened online by authorised officials of the Purchaser as per schedule given in Date Sheet.

1.20.2 In case, the day of bid opening is declared a holiday by the government, the E-bids will be opened on the next working day at the same time. No separate intimation shall be sent to the bidders in this regard.

1.20.3 Since, E-bid is an online process; the E-bid opening or any other process may be delayed due to any technical/server issue. If any such issue arises, this will not be tantamount to process delay and CSIR-NAL will not be responsible for the same.

1.20.4 On opening of bids online, accepting the bid will not mean that the firm is technically or financially qualified.

1.21 **Confidentiality**

1.21.1 Information relating to the examination, evaluation, comparison, and post qualification of bids, and recommendation of contract award, shall not be disclosed to bidders or any other persons not officially concerned with such process until Award of the Contract.

1.21.2 Any effort by a Bidder to influence the Purchaser in the examination, evaluation, comparison, and post qualification of the bids or contract award decisions may result in the rejection of its Bid.

1.22 **Clarification of Bids**

1.22.1 To assist in the examination, evaluation, comparison and post qualification of the bids, the Purchaser may, at its discretion, ask the Bidder for any clarification of its bid. The request for

clarification and the response shall be in writing and no change in prices or substance of the bid shall be sought, offered or permitted. However, no negotiation shall be held except with the lowest bidder, at the discretion of the purchaser.

1.22.2 Any clarification submitted by a bidder in respect to its bid which is not in response to a request by the purchaser shall not be considered. However, no post Bid clarifications at the initiative of the Bidder shall be entertained.

1.23 **Preliminary Examination**

(i) The Purchaser will examine the bids to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed, and whether the bids are generally in order. Bids from Bidders, withoutproper documents shall be treated as non-responsive and rejected summarily.

(ii) The Purchaser may waive any minor informality/ deviation in specifications, non-conformity, or irregularity in a bid, which does not constitute a material deviation, provided such a waiver, does not prejudice or affect the relative ranking of any Bidder.

(iii) Prior to the detailed evaluation, the Purchaser will determine the ***substantial responsiveness*** of each bid to the Bid Document. For purposes of these Clauses, a substantially responsive bid is one, which conforms to all the terms and conditions of the Bid Document without material deviations. Deviations from or objections or reservations to critical provisions such as those concerning Bid Security/ Performance Security, Certifications, Performance Requirements, applicable Law and Taxes & Duties will be deemed to be a material deviation. The Purchaser's determination of a bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence.

(iv) If a bid is not substantially responsive, it will be rejected by the Purchaser and may not subsequently be made responsive by the Bidder by correction of then on-conformity.

(v) After downloading, the language of standard clauses etc. mentioned in this 'Bid Document' should not be tempered with/ changed/modified in any manner whatsoever. If any such modification etc. comes to our knowledge at any stage, the bid shall be rejected immediately and EMD shall also be forfeited.

1.23.1 Bidders are expected to read through the Bid document carefully. All the Bids received will first be scrutinized to verify whether the tenders meet the basic requirements as incorporated in this Bid Document. The bids which do not meet the basic requirements will be treated as **non-responsive and ignored WITHOUT giving any opportunity for clarifications or rectification of errors etc.** The following are some of the points for which a tender will be declared as un-responsive and ignored during the initial scrutiny.

S. N.	Documents
a)	The bid is un-signed or has not been submitted in the desired format as per this document.
b)	The requisite EMD or the bid validity is shorter than the required period.
c)	The Bidder has not agreed to give the required performance security.
d)	The bidder has not agreed to some essential conditions incorporated in the bid document.
e)	If there is inconsistency between the Techno-Commercial Bid and Price Bid information / details.
f)	If the bidder has suppressed any material information / fact having relevance to the submitted bid or bidder performance
g)	If the bid is not submitted as per 'Format of Rates' or the format is changed in

	any way
i)	If the bidder has suppressed any material information / fact having relevance to the submitted bid or bidder performance.
j)	**OTHER POINTS OF SUMMARY REJECTION ARE ALSO MENTIONED IN THIS CHAPTER AND UNDER ELIGIBILITY CONDITIONS**

1.23.2 In case of two-bid system Bid Form and Price Schedule forms shall be examined after opening of the Price Bids of the technically qualified bidders.

1.24 **Responsiveness of Bids**

1.24.1 Prior to the detailed evaluation, the purchaser will determine the substantial responsiveness of each bid to the bidding documents. For purposes of this clause, a substantive responsive bid is one, which conforms to all terms and condition of the bidding documents without material deviations, reservations, or omissions.

1.24.2 The Purchasers' determination of a bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence.

1.24.3 If a bid is not substantially responsive, it will be rejected by the Purchaser and may not subsequently be made responsive by the Bidder by correction of the material deviation, reservation or omission.

1.25 **Non-Conformity, Error and Omission**

1.25.1 Provided that a Bid is substantially responsive, the Purchaser may waive any non-conformities or omissions in the Bid that do not constitute a material deviation.

1.25.2 Provided that a bid is substantially responsive, the Purchaser may request that the Bidder submit the necessary information or documentation, within a reasonable period, to rectify non-material non-conformities or omissions in the bid related to documentation requirements. Such omission shall not be related to any aspect of the price of the Bid. Failure of the Bidder to comply with the request may result in the rejection of its Bid.

1.25.3 The Purchaser shall correct arithmetical errors as per standard government guidelines or as per the methodology given on CPPP for this.

1.25.4 Provided that a bid is substantially responsive, the purchaser may request that a bidder may confirm the correctness of arithmetic errors as done by the purchaser within a target date. In case, no reply is received then the bid submitted shall be ignored and its Bid Security may be forfeited.

1.26 **Examination of Terms & Conditions and Technical Evaluation**

1.26.1 The Purchaser shall examine the Bid to confirm that all terms and conditions specified in the GCC have been accepted by the Bidder without any material deviation or reservation.

1.26.2 The Purchaser shall evaluate the technical aspects of the Bid submitted, to confirm that all requirements specified in "Scope of services, Qualification & eligibility criteria and Terms & conditions" of the Bidding Documents have been met without any material deviation or reservation.

1.26.3 If the Purchaser determines that the Bid is not substantially responsive in accordance with ITB Clauses 1.23 and 1.24, it shall reject the Bid summarily and no opportunity will be provided for any clarifications etc.

1.27 Evaluation and comparison of bids

1.27.1 The Purchaser shall evaluate each bid that has been determined, up to this stage of the evaluation, to be substantially responsive.

1.27.2 To evaluate a Bid, the Purchaser shall only use all the factors, methodologies and criteria defined below. No other criteria or methodology will be used.

1.27.3 The bids shall be evaluated on the basis of final landing cost which shall be arrived as under:

1.28 Evaluation criteria (QCBS method)

1.28.1 Evaluation Methodology: The bids shall be evaluated using the Quality-Cum-Cost Based Selection (QCBS) method with the following weightage:
Technical Score (TS): 50% (100 marks)
Financial Score (FS): 50% (100 marks)

1.28.2 Only those bidders who meet all the Qualification and Eligibility Criteria and score at least 50 marks out of 100 in the Technical Evaluation shall be considered Technically Qualified. Financial Bids of only Technically Qualified bidders shall be opened.

1.29 Comparison of Bids

1.29.1 The Purchaser shall compare all substantially responsive bids to determine the lowest valuated bid.

1.30 Contacting the Purchaser

1.30.1 No Bidder shall contact or attempt to contact the Purchaser or anyone related to the Purchaser onany matter relating to its bid, from the time of the bid opening to the time the Contract is awarded. If the bidder wishes tobring additional information to the notice of the Purchaser, it should do so in writing.

1.30.2 Any effort by a Bidder to influence the Purchaser in its decisions on bid evaluation, bid comparison or contract award may result in rejection of the Bidder's bid.

1.31 Post qualification

1.31.1 In the absence of pre-qualification, the Purchaser will determine to its satisfaction whether the Bidder that is selected as having submitted the lowest evaluated responsive bid is qualified to perform the contract satisfactorily, in accordance with the criteria listed in the document. The determination will take into account the Eligibility & Qualification criteria listed in the bidding documents and will be based upon an examination of the documentary evidence of the Bidder’s qualifications submitted by the Bidder, as well as such other information as the Purchaser deems necessary and appropriate.

1.31.2 An affirmative determination will be a prerequisite for award of the contract to the Bidder. A negative determination will result in rejection of the Bidder’s bid.

F. Award of contract

1.32 Negotiations

Director, CSIR-NAL reserves the right for commercial discussion with the lowest responsive bidder only, if considered appropriate and as per rules.

1.33 Award Criteria

The Purchaser will award the contract to the successful Bidder whose bid has been determined to be substantially responsive and has been determined to be the lowest evaluated bid, provided further that the Bidder is determined to be qualified to perform the contract satisfactorily. The details of the award would be hosted on the CPPP and NAL websites.

1.34 **Purchaser's right to accept any Bid and to reject any or all Bids**

The Purchaser reserves the right to accept or reject any bid, and to annul the bidding process and reject all bids at any time prior to award of Contract, without thereby incurring any liability to the affected Bidder or Bidders of the grounds for the Purchaser's action

1.35 Notification of Award

1.35.1 Prior to the expiration of the period of bid validity, the Purchaser will notify the successful bidder in writing by registered letter or e mail that the bid has been accepted and a separate purchase order shall follow through post.

1.35.2 Until a formal contract is prepared and executed, the notification of award should constitute a binding contract.

1.35.3 Upon the successful Bidder's furnishing of the signed Contract Form and Performance Security, the Purchaser will promptly notify each unsuccessful Bidder and discharge its bid security.

1.36 Signing of Contract

1.36.1 Promptly after notification, the Purchaser shall send the successful Bidder the Purchase Order.

1.36.2 Within twenty-one (21) days of date of the Purchase Order, the successful Bidder shall enter into Contract Agreement.

1.37 Order Acceptance

1.37.1 The successful bidder should submit Order acceptance within 15 days from the date of issue of Purchase Order, failing which it shall be presumed that the bidder is not interested and his bid security is liable to be forfeited or action as per BSD conditions shall be intitiated.

1.37.2 The order acceptance must be received within 15 days. However, the Purchaser has the powers to extend the time frame for submission of order acceptance and submission of Performance Security (PS). Even after extension of time, if the order acceptance / PS are not received, the contract shall be cancelled and limited tenders irrespective of the value shall be invited from the responding firms after forfeiting the bid security of the defaulting firm, where applicable, provided there is no change in specifications. In such cases the defaulting firm shall not be considered again for re-tendering in the particular case.

1.38 Assistance to Bidders:

1.38.1 Any queries relating to the process of online bid submission or queries relating to CPP Portal in general may be directed to the 24x7 CPP Portal Helpdesk.

G. GENERAL CONDITIONS OF CONTRACT

1.39 Definitions

Sr. No.	Words / Expressions	Meaning
(a)	Contract	The Contract Agreement entered into between the Purchaser and the Supplier, together with the Contract Documents referred to therein, including all attachments, appendices, and all documents incorporated by reference therein.
(b)	Contract Documents	The documents listed in the Contract Agreement, including any amendments thereto.
(c)	Contract Price	The price payable to the Supplier as specified in the Contract Agreement, subject to such additions and adjustments thereto or deductions there from, as may be made pursuant to the Contract.
(d)	Day	Calendar day
(e)	Completion	The fulfilment of the Related Services by the Supplier in accordance with the terms and conditions set forth in the Contract.
(f)	GCC	The General Conditions of Contract.
(h)	Services	As per the scope of services **DPSP** mentioned elsewhere in this document
(i)	SCC	The Special Conditions of Contract.
(l)	Council	The Council of Scientific & Industrial Research (CSIR), registered under the Societies Registration Act, 1860 of the Government of India having its registered office at 2, Rafi Marg, New Delhi-110001, India.
(m)	Purchaser	Director CSIR-NAL, HAL Airport Road, Kodihalli Bangalore, Karnataka
(n)	Custom Duty	Custom Duty in this bid document refers to the amount of Customs Duty plus the applicable IGST as per rules even if not mentioned explicitly.

1.40 Contract Documents

1.40.1 Subject to the order of precedence set forth in the Contract Agreement, all documents forming the Contract (and all parts thereof) are intended to be correlative, complementary, and mutually explanatory. The Contract Agreement shall be read as a whole.

1.40.2 Successful bidder shall have to enter into Contract Agreement on Rs.500/- non judicial stamp paper duly notarised as per Contract Form within 21 days of placement of Purchase Order.

1.41 JV, Consortium or Association/ Amalgamation/ Acquisition, Patent Indemnity etc.

1.41.1 If the Supplier is a joint venture, consortium, or association, all of the parties shall be jointly and severally liable to the Purchaser for the fulfilment of the provisions of the Contract and shall designate one party to act as a leader with authority to bind the joint venture, consortium, or association. The composition or the constitution of the joint venture, consortium, or association shall not be altered without the prior consent of the Purchaser.

1.41.2 **Amalgamation/ Acquisition etc.:**

In the event the Manufacturer/Supplier proposes for amalgamation, acquisition, or sale its business to any firm during the contract period, the Buyer/Successor of the Principal Company are liable for execution of the contract and fulfilment of contractual obligations i.e. supply, installation, commissioning, warranty, maintenance/replacement of spares accessories etc. You may confirm this condition while submitting the bid.

1.42 **Application**

These General Conditions shall apply to the extent that they are not superseded by provisions in other parts of the Contract.

1.43 Performance Security (PS)

1.43.1 Within 21 days of receipt of the notification of award of contract, the DPSP shall furnish performance security in the Performance Security Form provided in the Bid document.

1.43.2 The proceeds of the performance security shall be payable to the Purchaser as compensation for any loss resulting from the DPSP's failure to complete its obligations under the Contract.

1.43.3 The Performance security shall be in form as allowed under GFR 2017 as amended from time to time.

1.43.4 The performance security will be discharged by the Purchaser and returned to the DPSP only after the expiry, subject to fulfilment of contractual obligations and no dues to CSIR-NAL from the DPSP. without levy of any interest. The Director, CSIR-NAL will have the discretion to invoke the provisions of the Performance Security for breach of Contract.

1.43.5 In the event of any contract amendment, the DPSP shall, within 21 days of receipt of such amendment, furnish the amendment to the performance security, rendering the same valid for the duration of the contract.

1.43.6 The order confirmation should be received within 15 days from the date of notification of award. However, the Purchaser has the powers to extend the time frame for submission of order confirmation and submission of Performance Security (PS). Even after extension of time, if the order acceptance and PS are not received, the contract may be cancelled and fresh tenders called. In such cases the defaulting firm would not be considered again for re-tendering in the particular case. Action as per EMD/BSD shall be initiated.

1.43.7 If the bidder chooses to submit the Performance Security in the form of Bank Guarantee, and then he should advise the banker issuing the Bank Guarantee to immediately send by Registered Post (A.D.) an unstamped duplicate copy of the Guarantee directly to the Purchaser with a covering letter to compare with the original BG for the correctness, genuineness, etc.

1.43.8 Failure of the successful bidder to accept the order shall constitute sufficient grounds for the annulment of the award and forfeiture of the bid security or action as per BSD and call for new bids

1.44 Assignment

The DPSP shall not assign, in whole or in part, its obligations to perform under the Contract, except with the Purchaser's prior written consent.

1.45 **Subcontracts**

The DPSP shall notify the Purchaser in writing of all subcontracts awarded under this Contract if not already specified in the bid. Such notification, in the original bid or later, shall not relieve the Supplier from any liability or duties or obligation under the Contract.

1.46 Liquidated Damages/ Penalty clause

1.46.1 Subject to Clause on Force Majeure, if the DPSP fails to perform the Services, The Director, CSIR-NAL reserves the right to deduct Liquidated damages @ 0.5% per week (Maximum penalty shall be 10%). The period for this will be calculated after 30 days, from the date of intimation by supplier about the readiness of the consignment for shipment.

1.46.2 The period for LD will be calculated after 15 days from the date of intimation by supplier about the readiness of the consignment for shipment.

1.46.3 As time is the essence of the contract, clearance and delivery of the shipment should be strictly adhered to. Otherwise, the bidder will forfeit PS and also LD clause will be applicable /enforced.

1.47 Termination for Default

1.47.1 The Purchaser may, without prejudice to any other remedy for breach of contract, by written notice of default sent to the DPSP, terminate the Contract in whole or part:

(a)	If the DPSP fails to render services specified in the contract, or within any extension thereof granted by the Purchaser pursuant to GCC Clause on Extension of Time;
(b)	If the DPSP fails to perform any other obligation(s) under the Contract
(c)	If the DPSP, in the judgment of the Purchaser has engaged in corrupt or fraudulent or collusive or coercive practices as defined in the bid document.

1.47.2 In the event the purchaser terminates the contract in whole or in part, he may take recourse to any one or more of the following action:

(a)	The Performance Security/ EMD will be forfeited;
(b)	The Pu99999rchaser may procure, upon such terms and in such manner as it deems appropriate, services similar to those undelivered, and the DPSP shall be liable for all available actions against it in terms of the contract.
(c)	However, the supplier shall continue to perform the contract to the extent not terminated.

1.48 Force Majeure

1.48.1 Notwithstanding the provisions of GCC Clauses relating to Extension of Time, Penalty and Termination for Default the Supplier shall not be liable for forfeiture of its Performance Security, Liquidated Damages or Termination for Default, if and to the extent that, its delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure.

1.48.2 For purposes of this Clause, "Force Majeure" means an event or situation beyond the control of the Supplier that is not foreseeable, is unavoidable, and its origin is not due to negligence or lack of care on the part of the Supplier. Such events may include, but not be limited to, acts of the Purchaser in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.

1.48.3 If a Force Majeure situation arises, the Supplier shall promptly notify the Purchaser in writing of such conditions and the cause thereof within 21 days of its occurrence. Unless otherwise directed by the Purchaser in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.

1.48.4 If the performance in whole or in part or any obligations under the contract is prevented or delayed by any reason of Force Majeure for a period exceeding 60 days, either party may at its option terminate the contract without any financial repercussions on either side.

1.49 Termination for Insolvency

The Purchaser may at any time terminate the Contract by giving written notice to the DPSP, if the DPSP becomes bankrupt or otherwise insolvent. In this event, termination will be without compensation to DPSP, provided that such termination will not prejudice or affect any right of action or remedy, which has accrued or will accrue thereafter to the Purchaser.

1.50 Termination for Convenience

The Purchaser, by written notice sent to the DPSP, may terminate the Contract, in whole or in part, at any time. The notice of termination shall specify that termination is for the Purchaser's convenience, the extent to which performance of the DPSP under the Contract is terminated, and the date upon which such termination becomes effective.

1.51 Integrity Pact

1.51.1 As per Central Vigilance Commission (CVC) directions, CSIR laboratories/institutes implements an Integrity Pact (IP) to ensure transparency, equity and competitiveness in major Public procurement having procurement value above Rs.3 (three) crores. The integrity pact envisages an agreement between the prospective bidders with the buyer committing the persons/officials of both the parties with an aim not to exercise any corrupt influence on any aspect of the contract. Only those bidders, who are willing to enter in to such an integrity pact with the Purchaser, would be competent to participate in the bidding.

1.51.2 The names and contact details of the Independent External Monitors (IEM) on the event of the need of IP is as detailed below.

Integrity Pact – The integrity pact to be signed on Company's Letter head, wherever applicable. However, efforts must be made to realize the objectives and spirits thereof.	
The name and contact details of the IEMs are as under:	
Shri Jagadip Narayan Singh, IAS (Retd.) C-54, Bharatendu Harischandra Marg, Anand Vihar, Delhi – 110 092 **Email:** jagadipsingh@yahoo.com	Shri Arun Kumar Gupta, Ex-CMS, SCI 68B, Nandanvan CHS Sector 17 Nerul, Navi Mumbai – 400 706 **Email:** guptaarun55@rediffmail.com

1.52 Settlement of Disputes

1.52.1 The Purchaser and the DPSP shall make every effort to resolve amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the Contract.

1.52.2 If, after twenty-one (21) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Purchaser or the DPSP may give notice to the other party of its intention to commence arbitration, as hereinafter provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given. Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be finally settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under the Contract.

1.52.3 The venue of the arbitration shall be the place from where the Purchase Order or Contract is issued.

1.52.4 Notwithstanding any reference to arbitration herein,

(a)	the parties shall continue to perform their respective obligations under the Contract unless they otherwise agree; **and**
(b)	the Purchaser shall pay any monies due the DPSP.

1.53 Governing Language

The Contract shall be written in English language which shall govern its interpretation. All correspondence and other documents pertaining to the Contract, which are exchanged by the parties, shall be written in the English language only.

1.54 Applicable Law / Jurisdiction

The Contract shall be interpreted in accordance with the laws of the Union of India and all disputes shall be **Bengaluru**, India.

1.55 Notices

1.53.1 Any notice given by one party to the other pursuant to this contract / order shall be sent to the other party in writing, e-mail or / and confirmed in writing to the Purchaser's address as under:-

The Director
CSIR- National Aerospace Laboratories
HAL Airport Road, Kodihalli, Bengaluru – 560017
Karnataka-India
Email: purchasek@nal.res.in, mkala@nal.res.in

1.53.2 A notice shall be effective when delivered or on the notice's effective date, whichever is later.

CHAPTER-2
SCOPE OF SERVICES, ELIGIBILITY & QUALIFICATION AND TERMS & CONDITIONS

1.1 General Scope

The appointed **Drug Procurement and Supply Partner (DPSP)** shall be responsible for the uninterrupted procurement, stocking, storage, distribution, dispensing and timely supply of all contractually mandated medicines, approved formulary items and allied pharmaceutical products covered under the Rate Contract.

The DPSP shall ensure continuous availability of medicines through an efficient supply chain, including procurement from approved manufacturers/authorised distributors, inventory management, warehousing, transportation and delivery/dispensing at the designated CSIR-NAL Health Centre pharmacy facility and other locations as specified by CSIR-NAL.

The DPSP shall possess proven capability in pharmaceutical procurement, inventory management, warehousing and distribution of medicines and shall comply with all applicable statutory and regulatory requirements.

Except where otherwise specified by CSIR-NAL, the DPSP shall be responsible for procurement, transportation, handling, storage and safe delivery of medicines, including maintenance of prescribed storage conditions and cold-chain requirements wherever applicable.

1.2 End-to-End Pharmacy Management

The scope shall broadly include:

a) Procurement of medicines from approved sources; b)
b) Quality assurance and quality control;
c) Inventory planning and stock replenishment;
d) Order processing and dispensing;
e) Transportation and distribution;
f) Maintenance of adequate buffer stock;
g) Compliance with applicable pharmaceutical regulations;
h) Batch-wise documentation and traceability;
i) Demand forecasting and order fulfilment in coordination with CSIR-NAL;
j) Maintenance of stock and consumption records;
k) Submission of periodic reports on stock position, consumption, deliveries and other performance indicators; and
l) Ensuring uninterrupted availability of medicines throughout the contract period.

The primary objective of the Rate Contract is to facilitate transition of the **CSIR-NAL Health Centre pharmacy operations** from the existing fragmented procurement arrangement involving multiple suppliers to a streamlined **Single Window Pharmacy Management System (SWPMS)** operated through one contractual arrangement and governed by defined Service Level Agreements (SLAs).

2.0 PERIOD OF CONTRACT

2.1 Initial Contract Period

The Rate Contract shall remain valid for a period of **one (1) year** from the date of formal execution of the contract or from the mutually agreed operational commencement date of pharmacy operations, as determined by CSIR-NAL.

2.2 Extension/Renewal

The contract may be renewed for a further period of **one (1) year**, subject to satisfactory performance of the DPSP and retention of the same terms, conditions and prices by the DPSP.

2.3 Trial Period

The Director, CSIR-NAL, reserves the right to assess the performance of the successful bidder by initially awarding a temporary contract for a period of up to **six (6) months**, before granting the contract for the full duration.

2.4 Transitory Period

Upon completion of the contract period, including any extended period, CSIR-NAL reserves the right to enforce a mandatory transition arrangement for a period not exceeding **three (3) months**.

During the transition period, the DPSP shall maintain uninterrupted pharmacy services under identical commercial conditions, operational hours and category-wise discount rates.

3.0 OPERATIONAL HOURS AND FACILITY AVAILABILITY

3.1 Daily Operating Hours

The on-campus pharmacy facility operated under SWPMS shall remain functional from **08:30 hours to 20:30 hours on all working days**, unless otherwise directed in writing by CSIR-NAL.

3.2 Continuity of Service

The pharmacy counter shall remain open and fully staffed throughout the specified operational window without midday closure or service interruption. The DPSP shall arrange staff rotation/shifts internally to ensure seamless operation during peak dispensing hours.

4.0 SERVICE DELIVERY AND SUPPLY TURNAROUND

4.1 Emergency Medicine Supply

If a prescribed medicine is temporarily unavailable in the on-campus stock, the DPSP shall procure and supply the medicine within a maximum turnaround time of **24 hours**.

The authority to classify a medicine as an emergency medicine shall rest exclusively with the **Chief Medical Officer (CMO), CSIR-NAL Health Centre**.

4.2 Routine/Non-Emergency Medicine Supply

For non-emergency medicines and routine medical consumables temporarily out of stock, the DPSP shall complete procurement and supply within a maximum period of **seven (7) days**.

4.3 Range of Medicines and Consumables

The DPSP shall maintain continuous inventory and supply a comprehensive range of pharmaceutical products and medical consumables required for institutional healthcare services, including:

a) Routine medicines;
b) Chronic disease management medicines;
c) Specialty and super-specialty formulations;
d) Vaccines;
e) Biologicals;
f) Immunotherapy drugs;
g) Targeted oncological therapies; and
h) Other approved medicines and medical consumables covered under the CSIR-NAL formulary.

4.4 Formulary Continuity

The DPSP shall ensure continuous availability of all strengths, dosage forms and packaging configurations included in the CSIR-NAL Approved Formulary.

The DPSP shall implement appropriate procurement planning, stock rotation and risk-mitigation measures to minimise disruption arising from market or supply-chain constraints.

5.0 BENEFICIARY MEDICINE ACCESS

5.1 Beneficiaries within Bengaluru Urban and Bengaluru Rural Districts

For eligible pensioners and serving employees residing within the combined territorial limits of Bengaluru Urban and Bengaluru Rural districts, the DPSP shall provide the following options:

Option A – On-Campus Dispensation

Immediate collection of prescribed medicines from the central SWPMS on-campus counter during the prescribed operational hours.

Option B – Doorstep Delivery

Direct delivery of verified prescription medicines to the pensioner's residence without any additional logistics, transportation or handling charges.

Option C – City Retail Network Collection

Free collection of prescribed medicines by the beneficiary from any operational retail pharmacy outlet owned or operated within the DPSP's verified corporate network in Bengaluru.

The city-wide collection facility shall be free of cost to the beneficiary and CSIR-NAL and shall operate at the same flat contract discount rates.

5.2 Outstation Beneficiaries

For pensioners residing outside Bengaluru or serving employees on approved institutional leave temporarily located outside Bengaluru, the DPSP shall dispatch medicines through postal or secure parcel delivery services within standard commercial shipping timelines.

Such dispatches may be subject to nominal logistics charges as determined and authorised by CSIR-NAL.

6.0 100-DAY PARALLEL IMPLEMENTATION AND TRANSITION

To ensure uninterrupted healthcare delivery, the transition from the existing arrangement to the digital SWPMS model shall be undertaken through a phased **100-day parallel implementation programme**.

6.1 Phase I – Infrastructure Handover and Inventory Baseline

Days 1–20

a) CSIR-NAL shall provide managed access to the designated on-campus pharmacy premises, including existing cupboards, pharmacy racks and storage fixtures.
b) The DPSP shall conduct a comprehensive physical audit of existing institutional drug stocks along with the Health Centre administration.
c) Historical consumption patterns shall be mapped for inventory planning.

6.2 Phase II – Digital Architecture Alignment and Integration

Days 21–45

d) The DPSP shall install terminal hardware and deploy the digital window interface on-site without disturbing active medical counters.
e) Network synchronisation and API integration shall be undertaken with the central server for secure prescription data transmission.

6.3 Phase III – Mock Dry Runs and System Optimisation

Days 46–75

A dedicated testing window shall be utilised for mock dry runs of the digital workflow, including:

f) QR-code hashing;
g) Encryption validation;
h) Digital record transmission; and
i) Deactivation mechanisms.

At Days 60 and 70, a joint technical review committee chaired by the CMO and Purchase staff shall issue feedback logs identifying system bugs, interface delays or synchronisation errors.

The DPSP shall complete necessary code corrections, database adjustments and validation fixes within **five (5) working days** of each feedback log.

6.4 Phase IV – Staff Shadowing and Parallel Operation

Days 76–99

The DPSP shall deploy certified pharmaceutical personnel to the on-campus counters to shadow existing staff.

Prescriptions shall be processed through a live parallel framework, utilising the legacy dispensing workflow along with the digital QR verification loop as a live verification backup.

6.5 Phase V – Go-Live

Day 100

Complete operational cutover to the **Single Window Pharmacy Management System (SWPMS)** shall be undertaken.

The DPSP shall assume standalone responsibility for end-to-end pharmacy operations, digital logging and automated reconciliation.

6.6 Transition Milestones

Milestone	Core Implementation & Scrutiny Activity	Target Completion Deadline
M-01	Verification of corporate drug licenses (Form 19/19A and 20B/21B) and institutional site access clearance.	Day 10
M-02	Complete baseline audit of historical formulary logs and asset handover of existing campus racks/fixtures.	Day 20
M-03	On-site integration of terminal hardware and network connectivity alignment with the central prescription server.	Day 45
M-04	Launch of live Mock Dry Runs and structural stress-testing of the encrypted prescription QR-code loops	Day 55
M-05	**Review Loop I:** Issuance of first institutional feedback log by CSIR-NAL and execution of required software system rectifications.	Day 65
M-06	**Review Loop II:** Final validation of digital record retention protocols and automated transaction deactivation loops.	Day 75
M-07	Commencement of live parallel counter operations and on-site shadowing by DPSP pharmaceutical technicians.	Day 80
M-08	Final performance sign-off and system authorization certificate issued jointly by the CMO and Stores & Purchase Officer.	Day 95
M-09	**Official Go-Live Date:** STANDALONE LAUNCH of the Single Window Pharmacy Management System (SWPMS).	Day 100

7.0 ON-CAMPUS PREMISES AND INFRASTRUCTURE

7.1 Premises

CSIR-NAL shall provide designated premises within the campus for exclusive operation of the SWPMS facility.

The premises shall be provided to the DPSP free of rent, water charges, electricity charges, maintenance fees and property overheads.

7.2 Existing Infrastructure

The DPSP may utilise the existing infrastructure available within the dispensary premises, including furniture, pharmacy racks, security storage units, air-conditioning equipment and basic workspace utilities.

7.3 Restrictions on Modification

The DPSP shall not undertake any structural modification, building alteration or permanent layout addition without prior written approval of the competent authority of CSIR-NAL.

Portable/removable upgrades shall be undertaken at the cost of the DPSP.

Permanent structural modifications, where specifically authorised, may be funded by CSIR-NAL subject to administrative approval and budgetary provision.

7.4 Exclusive Use

The premises shall be used exclusively for stocking and dispensing approved formulary medicines and valid clinical medical consumables.

Storage, display or sale of cosmetics, food products, non-medical consumer items or other general commercial merchandise shall not be permitted.

8.0 QUALITY ASSURANCE, SHELF LIFE AND EXPIRY CONTROL

8.1 Minimum Shelf Life

All medicines, medical consumables and related clinical items supplied or dispensed shall have a minimum remaining shelf life of **30 days at the time of dispensing**.

Dispensing of products below this threshold shall not be permitted except where a specific written exception is authorised by the CMO under urgent clinical circumstances.

8.2 Replacement of Near-Expiry Stock

Where an item already dispensed to an eligible beneficiary subsequently falls below the 30-day remaining shelf-life requirement but has more than seven days before absolute expiry, the beneficiary shall be permitted to return the item for immediate replacement with fresh stock.

The replacement shall be made at no additional cost to the beneficiary or CSIR-NAL.

8.3 Stock with Seven Days or Less Shelf Life

Medicines having a remaining shelf life of **seven (7) days or less** shall be treated as non-dispensable.

Such items shall be isolated from dispensing stock and disposed of in accordance with applicable statutory requirements.

8.4 Substandard/Damaged Medicines

If any medicine, vaccine batch or surgical consumable supplied is certified by the CMO as substandard, damaged or unsuitable for human use, the DPSP shall replace the same at its own cost.

Replacement shall be completed within:

- **24 hours** for emergency medicines; and
- **7 days** for non-emergency/routine medicines.

8.5 Brand/Formulation Substitution

The DPSP shall not unilaterally substitute any branded formulation, generic equivalent or alternate drug molecule.

Any proposed substitution necessitated by temporary market scarcity shall be submitted to the CMO for clinical verification and explicit approval before dispensing.

8.6 Inspection

The CMO or designated medical personnel shall have the right to conduct periodic and unannounced inspections of the pharmacy facility, including storage conditions, cleanliness, inventory tracking and refrigeration arrangements.

9.0 DIGITAL SINGLE WINDOW PHARMACY MANAGEMENT SYSTEM

The SWPMS shall operate as a closed-loop digital tracking system to ensure transparency, prevent inventory diversion, avoid duplicate dispensing and minimise prescription forgery.

9.1 Prescription Generation

Only authorised Medical Officers of the CSIR-NAL Health Centre shall be permitted to generate prescriptions through the SWPMS.

Each prescription shall be digitally logged and authenticated through the prescribed validation mechanism.

9.2 Encrypted QR Code

After validation, the system shall generate a unique, single-use encrypted QR Code containing, inter alia:

a) Beneficiary identification details;
b) Prescribing Medical Officer details;
c) Prescribed medicines, strengths, dosage and quantities; and
d) System generation date and timestamp.

9.3 Transmission

The prescription and QR Code shall be transmitted to the beneficiary through registered mobile number by SMS and/or verified email.

9.4 Three-Level Record Retention

Three secure copies of the transaction record shall be maintained:

a) Clinician dashboard;
b) DPSP dispensing portal; and
c) Independent CSIR-NAL central administrative server.

9.5 Scanning and Dispensing

The DPSP technician shall scan the QR Code at the dispensing counter.

The system shall retrieve the prescription details for verification and the DPSP shall dispense only the medicines, strengths, dosage and quantities authorised in the digital prescription.

9.6 Reconciliation and QR Deactivation

After physical handover of medicines, the DPSP technician shall record the clearance confirmation in the system.

The transaction shall be reconciled with the central database and the QR Code shall thereafter be permanently deactivated to prevent reuse or duplicate dispensing.



10.0 RETURNS AND STOCK ADJUSTMENT

All authorised returns, replacements, near-expiry returns and CMO-certified substandard medicine returns shall be recorded electronically.

Each reverse transaction shall be linked to:

a) The original prescription;
b) QR-code tracking record; and
c) Inventory stock ledger.

Replacement items shall be linked to the unique identification of the original transaction to maintain complete traceability and audit compliance.

11.0 DIGITAL RECORD RETENTION AND AUDIT

The DPSP shall maintain unedited electronic records of:

a) Prescriptions;
b) Medicine dispensing transactions;
c) Billing records;
d) Inventory reconciliation; and
e) Other operational and commercial transactions.

All records shall be preserved for a minimum period of **five (5) years** from the transaction date or for such longer period as may be prescribed under applicable statutory requirements.

Recent transaction records shall remain readily searchable through the active system. Older records may be archived in secure databases/encrypted storage, provided they remain readily retrievable.

CSIR-NAL shall have the right to inspect, audit, sample, electronically review or obtain copies of digital records and transaction logs during the contract period and the prescribed retention period.

12.0 PERSONNEL AND LABOUR LAW COMPLIANCE

12.1 Employer-Employee Relationship

All pharmaceutical managers, technical personnel and desk staff deployed by the DPSP shall remain employees of the DPSP.

No employer-employee relationship shall exist between such personnel and CSIR-NAL.

12.2 Labour Law Compliance

The DPSP shall be solely responsible for compliance with applicable labour laws and welfare provisions, including statutory contributions towards ESI, PF and other applicable social security requirements.

12.3 CSIR-NAL Health Benefits

Personnel deployed by the DPSP shall not be entitled to participate in or claim benefits under the health schemes, dispensary facilities or medical reimbursement arrangements of CSIR-NAL.

Any medical expense, treatment liability or injury claim relating to DPSP personnel shall not be chargeable to CSIR-NAL.

13.0 INSURANCE AND LOGISTICS

The DPSP shall obtain and maintain, at its own cost, appropriate commercial insurance coverage against fire, theft, inventory loss and public liability associated with pharmacy operations.

All external operational expenses, including transportation, freight, storage, customs clearance, import-related duties and other logistics/incidental charges associated with imported or specialty formulations, shall be borne entirely by the DPSP.

No incidental or handling charges shall be payable by CSIR-NAL or the beneficiaries.

14.0 GRIEVANCE REDRESSAL

The DPSP shall establish an accessible grievance redressal mechanism comprising:

a) Physical helpdesk at the pharmacy;
b) Designated service email address; and
c) Physical bound grievance register at the counter.

The DPSP shall immediately acknowledge grievances and undertake resolution within the prescribed institutional timelines.

A complete grievance and resolution register shall be maintained for inspection.

Repeated complaints, service delays and unresolved grievances may be considered in performance evaluation and may constitute grounds for termination or non-extension of the contract.

15.0 ELIGIBILITY AND QUALIFICATION CRITERIA

15.1 **Legal Entity**

The bidder shall be a legally valid entity registered under the Indian Companies Act, 1956/2013 or a duly registered partnership/proprietary firm with an unblemished corporate record.

The bidder shall comply with the Pharmacy Act, 1948, Drugs and Cosmetics Act, 1940, Drugs and Cosmetics Rules, 1945 and applicable Central/State health department requirements.

Joint ventures or unverified broker syndicates shall not be eligible.

15.2 **Mandatory Licences and Registrations**

The bidder shall possess valid and current licences/registrations required for procurement, warehousing, distribution and retail dispensing of medicines.

The following shall be submitted along with the Technical Bid:

a) **Retail Drug Licence:** Form 19 and Form 19A;
b) **Wholesale Drug Licence:** Form 20B and Form 21B;
c) **GST Registration Certificate (GSTIN);** and
d) **PAN.**

Bids not accompanied by the prescribed active licences shall be liable for technical disqualification, subject to the Purchaser's right to seek clarification or permit conditional extension where considered necessary for strategic continuity.

15.3 **Retail Pharmacy Network**

The bidder shall possess and maintain not fewer than **100 fully operational retail pharmacy outlets** within the combined territorial limits of Bengaluru Urban and Bengaluru Rural districts.

Documentary evidence such as branch address matrix, geo-location records and municipal trading licences shall be submitted for the claimed outlets.

15.4 **Government/Institutional Experience**

The bidder shall have a minimum of **three (3) years' continuous experience during the immediately preceding five (5) financial years** in bulk pharmaceutical supply operations or management of on-campus dispensaries.

Such experience shall be recognised only where executed directly with:

- Central/State Government Hospital;
- CGHS dispensary;
- PSU hospital; or
- Equivalent public-funded autonomous medical institution.

The bidder shall have executed pharmaceutical supplies of at least **₹50,00,000/- (Rupees Fifty Lakhs only)** during at least one continuous financial year.

The bidder shall submit relevant work orders, execution certificates/clearance records and Chartered Accountant certification.

15.5 **Financial Capacity**

The bidder shall have an average annual turnover of at least **₹1,00,00,000/- (Rupees One Crore only)** during the immediately preceding three financial years.

The bidder shall submit audited financial statements and Chartered Accountant-certified documents.

The net worth shall be positive and shall not have eroded by more than 30% during the preceding three financial years.

15.6 **Bank Solvency**

The bidder shall submit a Bank Solvency Certificate issued by its primary scheduled commercial bank, dated not more than **six (6) months prior to the date of publication of the tender**.

15.7 Blacklisting / Suspension:

- Any firm that is **blacklisted** or debarred with CSIR or any other **government organization** (including customs, income tax, or other statutory authorities) is **not eligible to apply**. Bids from such firms will be **summarily rejected.**
- A bidder must not have its DPSP license suspended in the preceding three years
- **Non-disclosure** of any such information will result in, Disqualification of the bid and **action as per BSD** at the bidding stage, **Termination of the contract** (if awarded) without notice, Imposition of **penalty for damages incurred** during the contract and Recovery of any **outstanding amounts** due to CSIR-NAL.

16.0 TECHNICAL EVALUATION

The Technical Evaluation Score (TES) shall carry a maximum of **50 marks**.

S.No.	Comprehensive Evaluation Criteria Description	Allotted Marks	Scoring Methodology
1	**Retail Pharmacy Network** Total verified operational retail outlets functioning inside Bengaluru limits under Clause 15.3.	**15 Marks**	• Less than 100 outlets = 0 marks • 100 to 150 outlets = 5 marks • 150 to 200 outlets = 10 marks • 200+ outlets = 15 marks
2	**Government & Institutional Experience** Years of continuous supply experience inside Central/State Govt or PSU medical facilities under Clause 15.4.	**10 marks**	• Less than 3 years of experience = 0 marks • to 5 years of experience = 5 marks • 5+ years of experience = 10 marks
3	**Historical Contract Value Volume** Highest single-year material supply execution value achieved within the Government/PSU sector.	**15 Marks**	• Less than 50 lakh value of supply = 0 marks • 50 lakhs to 1 crore value of supply = 5 marks • 1 crore to 2 crore value of supply = 10 marks • 2+ crore value of supply = 15 marks
4	**Statutory Licensing & Document Compliance** Verification of active corporate incorporations and primary drug licenses (Form 19/19A/20B/21B) under Clause 15.1 & 15.2	**10 Marks**	• All statutory licences upto date = 10 marks
TECHNICAL EVALUATION SCORE (TES)		**50 Marks**	

17.0 COMMERCIAL PRICING STRUCTURE

The DPSP shall quote an independent **flat percentage discount on MRP** for each of the following seven categories. Evaluation will be based on a Composite Financial Score (CFS) mapped out of a maximum of 50 Marks.:

Category Reference	Target Evaluation Category	Allocated Marks (Mi)
Category 1 (C1)	Essential Primary Care & General Therapeutics	10 Marks
Category 2 (C2)	Life-Saving & Emergency Medications	10 Marks
Category 3 (C3)	Vaccines & Immunological Biologics	05 Marks
Category 4 (C4)	Controlled Substances & Narcotics	05 Marks
Category 5 (C5)	Specialized Antineoplastics & Immunosuppressives	10 Marks
Category 6 (C6)	Surgical & Medical Consumables	05 Marks
Category 7 (C7)	Diagnostic Reagents & Laboratory Consumables	05 Marks
	TOTAL	50 Marks

The quoted flat discount shall apply universally within the relevant category without brand-specific exceptions.

The final contract price shall be the MRP less the applicable category-wise discount and shall be inclusive of applicable taxes, logistics, freight, inventory handling, labour, insurance and all other incidental/operational expenses of the DPSP.

The bidder shall offer the discount applicable to, or ordinarily provided to, Government hospitals, institutions, and other Government organizations.

18.0 FINANCIAL EVALUATION

The Composite Financial Score (CFS) shall be calculated out of **50 marks**.

For each category:

$S_i = M_i \times (D_{\beta i}d,i / Dmax,i)$

Where:

- **Si** = Financial score obtained for Category i;
- **Mi** = Maximum marks allotted to Category i;
- **$D_{\beta i}d,i$** = Discount percentage quoted by the bidder for Category i; and
- **Dmax,i** = Highest discount percentage quoted by any technically responsive bidder for Category i.

The total Composite Financial Score shall be:

CFS = S1 + S2 + S3 + S4 + S5 + S6 + S7

19.0. TECHNO-COMMERCIAL EVALUATION AND AWARD

The final tender score shall be calculated as:

Combined Tender Score = Technical Evaluation Score (TES) + Composite Financial Score (CFS)

The maximum combined score shall be **100 marks**.

The qualified and responsive bidder securing the **Highest Combined Tender Score** shall be designated as the successful **H1 bidder** and recommended for award of the Rate Contract.

The contract shall be awarded in its entirety to one qualified and responsive bidder.

No category-wise or partial award shall be made.

In the event of a tie in the Combined Tender Score, preference shall be given to the bidder securing the higher **Technical Evaluation Score (TES)**.

20.0 STATUTORY DEDUCTIONS AND TAX COMPLIANCE

All payments shall be subject to statutory deductions at source in accordance with prevailing tax laws, rules and Government notifications.

The applicable deductions shall include, as relevant:

a) GST-TDS under applicable provisions of the CGST/KGST Acts;
b) Income Tax TDS under Section 194C of the Income Tax Act, 1961;
c) TDS under Section 194Q, wherever applicable; and
d) TDS under Section 194J, wherever applicable.

Where the DPSP fails to provide required evidence of filing of income tax returns, deductions shall be made in accordance with the applicable provisions of the Income Tax Act.

Note: The tax rates and thresholds specified in the source document should be revalidated against the statutory provisions prevailing on the date of tender/contract execution before final issue.

21.1 BILLING AND PAYMENT

21.1 Digital Billing

Invoices shall be generated through the synchronised digital system and shall correspond only to verified and authenticated medicine dispensing transactions recorded in the SWPMS.

21.2 Billing Cycle

Verified transactions shall be compiled and processed electronically on a **fortnightly or monthly basis**, as determined by the competent authority of CSIR-NAL.

21.3 Mandatory Invoice Details

Each invoice shall contain:

a) DPSP's full trading name, address and GSTIN;
b) CSIR-NAL billing details and GSTIN;
c) Unique invoice number and date;
d) HSN/SAC codes;
e) Item description, quantity and MRP; and
f) Calculation showing the applicable category-wise discount and final contract price.

21.4 Invoice Reconciliation

Flawed, altered, duplicate or otherwise irregular invoices may result in suspension of the relevant billing cycle pending reconciliation.

Where deliberate misrepresentation or fraudulent logging is established, CSIR-NAL may initiate appropriate contract-default action and invoke the Performance Security provisions in accordance with applicable institutional rules.

21.5 No Advance Payment

No advance payment, mobilisation advance, upfront financial transfer or minimum guaranteed billing shall be payable by CSIR-NAL.

The contract shall be strictly **transaction-driven and consumption-based**.

CSIR-NAL shall have no liability towards any minimum guaranteed purchase quantity or billing volume.

The DPSP shall finance the required inventory and operational setup through its own working capital, and payment shall be made in arrears against verified dispensing transactions.



22.0 GENERAL CONDITIONS

22.1 **Unconditional Acceptance**

The bidder shall provide explicit and unconditional acceptance of all operational requirements, digital system requirements, premises conditions and category-wise discount structure specified in the tender.

Conditional acceptance or qualified compliance shall render the bid liable for technical disqualification.

22.2 **Right of Rejection**

CSIR-NAL reserves the right to reject any bid that fails to comply with the legal, technical, licensing, financial, integrity or operational requirements of the tender.

CSIR-NAL may seek clarification or, where considered necessary in the overriding strategic or operational interest of the Institute, relax/waive/condone a requirement in writing.

22.3 Complete Responsibility of DPSP

The successful DPSP shall be responsible for complete execution of the Rate Contract, including procurement, stocking, quality assurance, dispensing, logistics, digital transaction recording, inventory management, replenishment, statutory compliance and reporting.

22.4 Continuity of Service

At no stage during the contract period or transition period shall the DPSP discontinue pharmacy operations or interrupt the supply of essential medicines without prior written approval of CSIR-NAL.

23.0 ACCEPTANCE OF TERMS

The bidder shall confirm that it has carefully examined and understood the entire scope, eligibility criteria, technical requirements, digital SWPMS framework, commercial terms, discount structure, payment conditions and other conditions of the Rate Contract and agrees to comply with the same without any deviation.

24.0 Schedule of Requirements (BoQ)

24.1 CATEGORY 1 (C1) - Essential Primary Care & General Therapeutics

Essential Primary Care & General Therapeutics			
S. No.	Therapeutic Group	Sub-Category	Scope / Description
1	Anti-infectives	Antibiotics	Medicines used for the prevention and treatment of bacterial infections.
2		Antitubercular Drugs	Medicines used for the treatment and prevention of tuberculosis.
3		Antileprosy Drugs	Medicines used for the treatment of leprosy.
4		Antifungal Drugs	Medicines used for fungal infections.
5		Antiviral Drugs	Medicines used for viral infections excluding HIV.
6		Antiretroviral Drugs	Medicines used for HIV/AIDS management.
7		Antimalarial Drugs	Medicines used for prevention and treatment of malaria.
8		Anthelmintics	Medicines used for helminth (worm) infestations.
9		Antiprotozoal Drugs	Medicines used for protozoal infections.
10		Antiparasitic Drugs	Medicines used for parasitic infestations.
11		Antiseptics	Skin and wound antiseptic preparations.
12		Disinfectants	Hospital-grade disinfectants and sterilizing agents.
13	Cardiovascular Medicines	Antihypertensives	Medicines used to control hypertension.
14		Antianginal Drugs	Medicines used for angina pectoris.
15		Antiarrhythmic Drugs	Medicines used to treat cardiac arrhythmias.
16		Heart Failure Medicines	Medicines used in congestive heart failure.
17		Diuretics	Medicines that promote urine excretion.
18		Vasodilators	Medicines that dilate blood vessels.
19		Lipid Lowering Agents	Medicines used to lower cholesterol and triglycerides.

20		Anticoagulants	Medicines used to prevent blood clot formation.
21		Antiplatelet Agents	Medicines that inhibit platelet aggregation.
22		Thrombolytic Agents	Medicines used to dissolve blood clots.
23	Endocrine & Metabolic Medicines	Antidiabetic Drugs	Oral medicines used in diabetes mellitus.
24		Insulins	Short-, intermediate-, and long-acting insulin preparations.
25		Thyroid Preparations	Medicines used for hypothyroidism.
26		Antithyroid Drugs	Medicines used for hyperthyroidism.
27		Corticosteroids	Systemic and topical corticosteroid preparations.
28		Hormonal Preparations	Hormonal medicines excluding insulin.
29		Osteoporosis Medicines	Medicines used for prevention and treatment of osteoporosis.
30	Gastrointestinal Medicines	Antacids	Medicines that neutralize gastric acid.
31		Proton Pump Inhibitors	Medicines that suppress gastric acid secretion.
32		H2 Receptor Antagonists	Histamine H2 receptor blockers.
33		Antiemetics	Medicines used to prevent nausea and vomiting.
34		Antispasmodics	Medicines used to relieve gastrointestinal spasms.
35		Laxatives	Medicines used to treat constipation.
36		Antidiarrhoeals	Medicines used to treat diarrhoea.
37		Digestive Enzymes	Enzyme preparations used in digestive disorders.
38		Oral Rehydration Salts	Oral electrolyte replacement solutions.

39		Hepatoprotective Agents	Medicines used in liver disorders.
40	Respiratory Medicines	Bronchodilators	Medicines used for asthma and COPD.
41		Antiasthmatics	Controller and reliever medicines for asthma.
42		Antihistamines	Medicines used in allergic conditions.
43		Expectorants	Medicines that facilitate sputum removal.
44		Mucolytics	Medicines that reduce mucus viscosity.
45		Antitussives	Medicines used to suppress cough.
46		Nasal Preparations	Nasal sprays and drops.
47	Central Nervous System Medicines	Antiepileptic Drugs	Medicines used to control seizures.
48		Antiparkinsonian Drugs	Medicines used in Parkinson's disease.
49		Anti-migraine Drugs	Medicines used for migraine treatment and prevention.
50		Anti-vertigo Drugs	Medicines used for vertigo and balance disorders.
51	Pain & Inflammation	Analgesics	Non-opioid pain-relieving medicines.
52		NSAIDs	Non-steroidal anti-inflammatory medicines.
53		Antipyretics	Medicines used to reduce fever.
54		Muscle Relaxants	Medicines used to relieve muscle spasm.
55		Anti-gout Medicines	Medicines used in gout management.
56	Dermatological Preparations	Topical Antibiotics	Antibiotic creams, ointments and lotions.
57		Topical Antifungals	Antifungal creams, lotions and powders.
58		Topical Corticosteroids	Steroid creams and ointments.
59		Emollients	Moisturizers and skin protectants.
60		Acne Preparations	Medicines used for acne treatment.
61		Scabicides & Pediculicides	Medicines used for scabies and lice infestations.

62	Ophthalmic Preparations	Ophthalmic Medicines	Eye drops, eye ointments and ophthalmic solutions.
63	ENT Preparations	ENT Medicines	Ear drops, nasal drops, gargles and throat preparations.
64	Dental Preparations	Dental Medicines	Oral gels, mouth paints, fluoride and dental preparations.
65	Obstetrics & Gynaecology Medicines	Maternal Health Medicines	Medicines used during pregnancy, labour and postpartum care.
66		Contraceptives	Oral, injectable, implantable and emergency contraceptives.
67	Urology & Nephrology Medicines	Urological Medicines	Medicines used in urinary tract and prostate disorders.
68		Renal Medicines	Medicines used in kidney diseases and renal replacement support.
69	Paediatric Medicines	Paediatric Formulations	Child-specific dosage forms and strengths.
70	Geriatric Medicines	Geriatric Preparations	Medicines commonly used in elderly patients.
71	Vitamins, Minerals & Nutrition	Vitamins	Water-soluble and fat-soluble vitamin preparations.
72		Mineral Supplements	Calcium, iron, zinc and other mineral preparations.
73		Nutritional Supplements	Protein supplements and enteral nutrition formulations.
74	Blood & Hematological Medicines	Hematinics	Iron, folic acid, vitamin B12 and related preparations.
75		Hemostatic Agents	Medicines used to control bleeding.
76		Plasma Expanders	Plasma volume replacement preparations.

77	Intravenous Fluids & Electrolytes	Intravenous Fluids	Crystalloid and maintenance IV fluids.
78		Electrolyte Solutions	Injectable electrolyte replacement preparations.
79	Diagnostic Agents	Contrast Media	Contrast agents used in radiological imaging.
80	Miscellaneous Therapeutics	Miscellaneous Medicines	Therapeutic agents not classified under the above groups.

24.2 CATEGORY 2 (C2) - Life-Saving & Emergency Medications

Life-Saving & Emergency Medications			
S. No.	Therapeutic Group	Sub-Category	Scope / Description
	Emergency Cardiovascular Medicines	Vasopressors	Medicines used to maintain blood pressure in shock and critical illness.
1			
2		Inotropes	Medicines used to improve cardiac contractility.
3		Cardiac Stimulants	Medicines used during cardiac emergencies and resuscitation.
4		Antiarrhythmic Emergency Drugs	Medicines used to treat life-threatening cardiac arrhythmias.
5		Antianginal Emergency Drugs	Medicines used in acute coronary syndromes and angina.
6		Antihypertensive Emergency Drugs	Medicines used in hypertensive emergencies.
		Thrombolytic Agents	Medicines used to dissolve blood clots in myocardial infarction, stroke and pulmonary embolism.
7			
8		Cardiac Glycosides	Medicines used in acute heart failure and selected arrhythmias.
	Emergency Respiratory Medicines	Emergency Bronchodilators	Medicines used in acute asthma and bronchospasm.
9			
10		Oxygen Therapy	Medical oxygen and oxygen delivery products used during emergencies.
11		Respiratory Stimulants	Medicines used to stimulate respiration in selected emergencies.

12	Emergency Allergy & Anaphylaxis	Anti-anaphylactic Medicines	Medicines used for anaphylaxis and severe allergic reactions.
13		Emergency Antihistamines	Injectable and oral antihistamines used in emergencies.
14		Emergency Corticosteroids	Corticosteroids used for severe allergic and inflammatory conditions.
15	Emergency Neurology	Emergency Anticonvulsants	Medicines used for status epilepticus and acute seizures.
16		Emergency Sedatives	Medicines used for emergency sedation.
17		Neuromuscular Blocking Agents	Medicines used during rapid sequence intubation and critical care.
	Emergency Anaesthesia	General Anaesthetic Agents	Medicines used for emergency induction of anaesthesia.
18			
19		Local Anaesthetic Agents	Local anaesthetics used during emergency procedures.
20	Emergency Fluids & Electrolytes	Intravenous Fluids	Crystalloids and colloids used for emergency fluid resuscitation.
21		Plasma Expanders	Solutions used to restore circulating blood volume.
22		Electrolyte Replacement Solutions	Injectable electrolyte preparations for emergency correction.
23		Hyperkalemia Management Medicines	Medicines used to rapidly reduce elevated serum potassium.
24		Hypoglycaemia Management Medicines	Injectable glucose and related medicines for hypoglycaemia.
25	Emergency Toxicology	Antidotes	Specific antidotes used for poisoning and overdose.
26	Emergency Toxicology	Chelating Agents	Medicines used in heavy metal poisoning.
27		Activated Charcoal	Gastrointestinal adsorbent used in selected poisonings.

28	Emergency Obstetrics	Obstetric Emergency Medicines	Medicines used during obstetric emergencies including postpartum haemorrhage and eclampsia.
29	Emergency Gastrointestinal	Emergency Antiemetics	Medicines used to control severe nausea and vomiting.
30		Emergency Acid Suppression Medicines	Injectable medicines used in acute gastrointestinal bleeding and stress ulcer prophylaxis.
31	Emergency Infectious Diseases	Broad-Spectrum Emergency Antibiotics	Immediate empirical antibiotic therapy for severe infections and sepsis.
32		Emergency Antiviral Medicines	Antiviral medicines used in life-threatening viral infections.
33	Emergency Endocrine	Emergency Steroids	Steroids used in adrenal crisis and severe inflammatory emergencies.
34		Emergency Insulins	Insulin preparations used in diabetic emergencies.
35	Emergency Blood Products	Blood Components	Packed red blood cells, plasma, platelets and cryoprecipitate used in emergencies.
36		Hemostatic Agents	Medicines used to control severe bleeding.
37	Intensive Care Medicines	Critical Care Medicines	Medicines used exclusively in ICU and emergency departments.
38		Resuscitation Medicines	Medicines required for Advanced Cardiac Life Support (ACLS) and Basic Life Support (BLS).
39		Emergency Infusions	Continuous intravenous infusions used in critically ill patients.
40	Miscellaneous Emergency Medicines	Other Emergency Medicines	Life-saving medicines not classified under the above therapeutic groups.

24.3 CATEGORY 3 (C3) - Vaccines & Immunological Biologics

Vaccines & Immunological Biologics			
S. No.	Therapeutic Group	Sub-Category	Scope / Description
1	Bacterial Vaccines	Live Attenuated Bacterial Vaccines	Vaccines containing live weakened bacteria for prevention of bacterial diseases.
2		Inactivated Bacterial Vaccines	Vaccines containing killed bacteria for immunization.

3		Toxoid Vaccines	Vaccines prepared from inactivated bacterial toxins.
4	Viral Vaccines	Live Attenuated Viral Vaccines	Vaccines containing live weakened viruses.
5		Inactivated Viral Vaccines	Vaccines prepared from killed viruses.
6		Recombinant Viral Vaccines	Vaccines developed using recombinant DNA technology.
7		mRNA Vaccines	Messenger RNA-based vaccines for infectious diseases.
8		Viral Vector Vaccines	Vaccines using viral vectors to deliver antigens.
9	Combination Vaccines	Pediatric Combination Vaccines	Vaccines protecting against multiple diseases in a single formulation.
10		Adult Combination Vaccines	Combination vaccines recommended for adults.
11	National Immunization Programme Vaccines	Universal Immunization Programme (UIP) Vaccines	Vaccines included under the Government of India Universal Immunization Programme.
12		Mission Indradhanush Vaccines	Vaccines supplied under Mission Indradhanush.
13	Travel Vaccines	International Travel Vaccines	Vaccines recommended or required for international travellers.
14	Occupational Vaccines	Healthcare Worker Vaccines	Vaccines recommended for healthcare professionals and laboratory personnel.
15	Immunoglobulins	Human Normal Immunoglobulin	Human immunoglobulin preparations for passive immunity.
16		Specific Immunoglobulins	Disease-specific immunoglobulin preparations (e.g., rabies, tetanus, hepatitis B).
17	Antisera	Anti-snake Venom	Serum used for treatment of snake envenomation.
18		Anti-rabies Serum	Passive immunization following rabies exposure.

19		Other Therapeutic Antisera	Antisera used for specific toxin or venom neutralization.
20	Antitoxins	Bacterial Antitoxins	Preparations used to neutralize bacterial toxins.
21	Monoclonal Antibodies	Preventive Monoclonal Antibodies	Monoclonal antibodies used for prevention of infectious diseases.
22		Therapeutic Monoclonal Antibodies	Monoclonal antibodies used for treatment of infectious and immune-mediated diseases.
23	Blood-Derived Biological Products	Plasma-Derived Products	Biological products derived from human plasma.
24		Coagulation Factor Preparations	Biological clotting factor concentrates.
25	Allergy Immunotherapy	Allergen Extracts	Biological preparations used for allergy desensitization.
26	Diagnostic Immunobiologicals	Tuberculin Preparations	Immunobiological products used for diagnostic testing.
27	Cold Chain Biologicals	Temperature-Sensitive Vaccines	Vaccines requiring storage between 2°C and 8°C.
28		Frozen Biological Products	Biological products requiring frozen storage conditions.
29	Emergency Biologicals	Outbreak Response Vaccines	Vaccines used during epidemics and public health emergencies.
30	Miscellaneous Immunological Products	Other Immunobiological Preparations	Vaccines and biological products not covered under the above categories.

24.4 CATEGORY 4 (C4) - Controlled Substances & Narcotics

Controlled Substances & Narcotics			
S. No.	Therapeutic Group	Sub-Category	Scope / Description
1	Opioid Analgesics	Strong Opioid Analgesics	Medicines used for severe pain requiring strict regulatory control.
2		Moderate Opioid Analgesics	Medicines used for moderate to severe pain under controlled prescription.
3		Weak Opioid Analgesics	Medicines used for mild to moderate pain with controlled dispensing.

4	Narcotic Analgesics	Injectable Narcotics	Injectable narcotic medicines used in surgery, ICU and emergency care.
5		Oral Narcotics	Oral narcotic formulations requiring statutory control.
6	Sedatives & Hypnotics	Benzodiazepines	Controlled medicines used for anxiety, seizures and procedural sedation.
7		Non-Benzodiazepine Hypnotics	Controlled medicines used for insomnia and procedural sedation.
8		Barbiturates	Controlled sedative and anticonvulsant medicines.
9	Psychotropic Medicines	Antipsychotic Controlled Medicines	Controlled psychotropic medicines used in psychiatric disorders.
10		Controlled Anxiolytics	Medicines used for anxiety disorders under controlled prescription.
11		Controlled Stimulants	Medicines used for ADHD and other approved indications requiring regulation.
12	Anaesthetic Agents	General Anaesthetic Agents	Controlled medicines used for induction and maintenance of anaesthesia.
13		Intravenous Anaesthetic Agents	Injectable anaesthetic medicines used in surgery and intensive care.
14		Inhalational Anaesthetic Agents	Volatile anaesthetic agents used in operating theatres.
15		Local Anaesthetic Agents	Controlled local anaesthetic medicines used for regional and local anaesthesia.
16	Muscle Relaxants	Neuromuscular Blocking Agents	Medicines used during surgery and mechanical ventilation.
17	Controlled Anticonvulsants	Schedule-Controlled Antiepileptics	Controlled anticonvulsant medicines requiring regulated storage.
18	Schedule X Medicines	Schedule X Antibiotics & Medicines	Medicines regulated under Schedule X of the Drugs & Cosmetics Rules.
19	Schedule H1 Medicines	Schedule H1 Antimicrobials	Medicines regulated under Schedule H1 requiring prescription records.

20	Schedule H1 Medicines	Schedule H1 Anti-Tubercular Medicines	Anti-TB medicines notified under Schedule H1.
21	NDPS Medicines	Narcotic Drugs	Medicines regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act.
22	NDPS Medicines	Psychotropic Substances	Psychotropic medicines regulated under the NDPS Act.
23	Controlled Emergency Medicines	Emergency Narcotic Medicines	Controlled medicines reserved for emergency and critical care use.
24	Controlled Oncology Medicines	Controlled Cancer Pain Medicines	Narcotic medicines used in palliative and oncology pain management.
25	Controlled Palliative Care Medicines	End-of-Life Care Medicines	Controlled medicines used in hospice and palliative care.
26	Controlled Obstetric Medicines	Controlled Medicines for Labour & Delivery	Controlled medicines used during obstetric procedures.
27	Controlled Veterinary Narcotics	Veterinary Controlled Medicines	Narcotic and psychotropic medicines intended for veterinary use (where applicable).
28	Regulatory & Compliance Medicines	Double Lock Storage Medicines	Medicines requiring secure double-lock storage and restricted access.
29		Register-Controlled Medicines	Medicines requiring mandatory stock registers, issue registers and audit trails.
30		Expired & Returned Controlled Medicines	Controlled medicines awaiting destruction, return or regulatory disposal.

24.5 CATEGORY 5 (C5) - Specialized Antineoplastics & Immunosuppressives

Specialized Antineoplastics & Immunosuppressives			
S. No.	Therapeutic Group	Sub-Category	Scope / Description
1	Cytotoxic Chemotherapy	Alkylating Agents	Cytotoxic medicines that inhibit cancer cell growth by alkylating DNA.
2		Antimetabolites	Medicines that interfere with DNA and RNA synthesis in rapidly dividing cells.
3		Antitumor Antibiotics	Cytotoxic antibiotics used in cancer chemotherapy.

4		Plant Alkaloids	Plant-derived anticancer medicines that inhibit cell division.
5		Taxanes	Anticancer medicines that stabilize microtubules and inhibit mitosis.
6		Platinum Compounds	Platinum-based anticancer medicines causing DNA cross-linking.
7		Topoisomerase Inhibitors	Medicines that inhibit DNA topoisomerase enzymes.
8		Miscellaneous Cytotoxic Agents	Other conventional cytotoxic anticancer medicines.
9	Targeted Therapy	Tyrosine Kinase Inhibitors (TKIs)	Targeted medicines acting on tyrosine kinase pathways.
10		Monoclonal Antibodies	Biological agents targeting specific cancer cell antigens.
11		Angiogenesis Inhibitors	Medicines that inhibit tumour blood vessel formation.
12		Proteasome Inhibitors	Medicines used mainly in multiple myeloma.
13		PARP Inhibitors	Targeted medicines used in selected hereditary cancers.
14		mTOR Inhibitors	Medicines targeting the mammalian target of rapamycin pathway.
15		CDK Inhibitors	Cyclin-dependent kinase inhibitors used in cancer treatment.
16	Immunotherapy	Immune Checkpoint Inhibitors	Medicines enhancing immune response against cancer cells.
17		CAR-T Cell Therapy	Genetically modified T-cell therapy for selected cancers.
18		Cytokine Therapy	Therapeutic cytokines used in oncology and immune disorders.

19	Hormonal Anticancer Therapy	Anti-estrogens	Hormonal therapy used mainly in breast cancer.
20		Aromatase Inhibitors	Medicines reducing estrogen synthesis.
21		Anti-androgens	Medicines used in prostate cancer management.
22		Gonadotropin-Releasing Hormone (GnRH) Analogues	Hormonal medicines used in hormone-dependent cancers.
23	Immunosuppressive Medicines	Calcineurin Inhibitors	Medicines used to prevent organ transplant rejection.
24		Antimetabolite Immunosuppressants	Medicines used for transplantation and autoimmune diseases.
25		mTOR Immunosuppressants	Immunosuppressive medicines used in transplant recipients.
26		Corticosteroid Immunosuppressants	Steroids used for immune suppression and transplant protocols.
27		Biologic Immunosuppressants	Monoclonal antibodies and biologics used to suppress immune responses.
28	Disease-Modifying Medicines	Conventional DMARDs	Disease-modifying medicines for autoimmune disorders.
29		Biologic DMARDs	Biological disease-modifying agents for rheumatologic diseases.
30		Targeted Synthetic DMARDs	Small-molecule targeted medicines for autoimmune diseases.
31	Supportive Oncology	Antiemetics	Medicines used to prevent chemotherapy-induced nausea and vomiting.
32		Colony Stimulating Factors	Medicines that stimulate white blood cell production after chemotherapy.
33		Erythropoiesis Stimulating Agents	Medicines used to treat chemotherapy-associated anaemia.

34		Bone-Modifying Agents	Medicines used to prevent skeletal complications in cancer.
35		Cytoprotective Agents	Medicines that reduce toxicity associated with chemotherapy.
36		Tumour Lysis Syndrome Medicines	Medicines used to prevent and treat tumour lysis syndrome.
37	Cellular & Gene Therapy	Stem Cell Therapy Products	Cellular therapy products used in oncology and hematology.
38		Gene Therapy Products	Advanced gene therapy medicinal products.
39		Oncolytic Viral Therapy	Viruses engineered to selectively destroy cancer cells.
40	Miscellaneous Oncology Products	Other Specialized Antineoplastics & Immunosuppressives	Specialized oncology and immunosuppressive medicines not covered under the above groups.

24.6 CATEGORY 6 (C6) - Diagnostic Reagents & Laboratory Equipment Consumables

Diagnostic Reagents & Laboratory Equipment Consumables			
S. No.	**Therapeutic Group**	**Sub-Category**	**Scope / Description**
1	Clinical Biochemistry Reagents (COBAS C111 Analyser)	Routine Biochemistry Reagents	Reagents used for Glucose, Urea, Creatinine, Liver function, Lipid profile, Uric acid, HbA1c and Electrolyte Analysis (Roche 9180).
2	Hematology Reagents (Sysmex)	CBC Reagents	Reagents used for complete blood count and automated hematology analysis. (Sysmex)
3		Blood Grouping Reagents	Reagents used for ABO, Rh typing
4	Microbiology Reagents	Staining Reagents	Gram stain, Ziehl-Neelsen stain
5	Laboratory Chemicals	Calibration Solutions	Standard solutions used for calibration of laboratory instruments.
6		Quality Control Materials	Internal and external quality control materials.
7		Sample Collection Tubes	Vacutainers, blood collection tubes. Needles (BD) and specimen containers. Lancet Needles
8		Pipette Tips	Disposable pipette tips for laboratory use.
9		Microscope Slides &	Glass slides and cover slips for

		Cover Slips	microscopy.
10		Test Tubes & Centrifuge Tubes	Tubes used for specimen processing and testing.
11	Instrument Consumables	Printer Paper & Labels	Consumables used for laboratory reporting systems.
12	Point-of-Care Testing (POCT)	Blood Glucose Test Strips	Glucose strips used with glucometers.
13		Urine Test Strips	Multi-parameter urine dipsticks. Combistix, Multi Stix
14		Pregnancy Test Kits	Rapid hCG detection kits.
15		Infectious Disease Rapid Test Kits	Rapid diagnostic kits for HIV, HBsAg, HCV, malaria, dengue, COVID-19 and Widal Test.
16		Cardiac kits	Trop-T Kits
17	Laboratory Safety Consumables	Biohazard Disposal Materials	Biohazard bags, sharps containers and waste management consumables.
18	Miscellaneous Laboratory Products	Other Diagnostic Reagents & Laboratory Consumables	Diagnostic reagents and laboratory consumables not covered under the above categories, Double Distilled Water and Micro Cuvette(COBAS C111), Urine Container

24.7 CATEGORY 7 (C7) - Surgical and Medical Cosumables (Nursing station)

24.7.1 Consumables & Dressings

Sterile gauze swabs
Sterile dressing pads
Cotton bandages
Elastic crepe bandages
Adhesive zinc oxide plaster
Absorbent cotton wool
Non-sterile gauze rolls
Wound dressing packs (if required)

24.7.2 Tapes

Paper surgical tape
Micropore tape
Transpore tape (heavy-duty)

24.7.3 Swabs & Cotton

Alcohol swabs
Povidone-iodine swabs
Sterile cotton balls

24.7.4 Nebulization & Oxygen Supplies

Adult nebulization mask
Pediatric nebulization mask
Oxygen nasal prongs (adult & pediatric)
Oxygen face masks (adult & pediatric)

24.7.5 Personal Protective Equipment (PPE) & Infection Control

Gloves
Powder-free examination gloves (latex/nitrile)
Powdered examination gloves
Sterile surgical gloves

24.7.6 Masks & Headwear

3-ply surgical masks
N95 respirators
Disposable bouffant caps
Disposable shoe covers

24.7.7 Gowns & Drapes

Disposable isolation gowns
Disposable patient drapes
Disposable aprons

24.7.8 Hygiene & Disinfection

Alcohol-based hand sanitizer
Antibacterial hand wash
Surface disinfectant (Sodium Hypochlorite)
Instrument disinfectant (Glutaraldehyde)
70% Isopropyl alcohol

24.7.9 Syringes, Needles & IV Administration

Disposable Syringes
mL
5 mL
10 mL
20 mL
50 mL

24.7.10 Hypodermic Needles

20G
22G
23G
24G
26G

24.7.11 IV Administration

Adult IV administration sets
Pediatric burette (Buretrol) IV sets
IV extension tubing
Double-lumen octopus connectors
Triple-lumen octopus connectors

24.7.12 IV Cannulas

18G
20G
22G
24G

24.7.13 Catheters & Drainage

Suction catheters
Foley urinary catheters (various sizes)
Infant feeding tubes (if required)
Surgical drains
Chest drainage tubes
Urine collection bags

24.7.14 Surgical & Diagnostic Instruments

Surgical Instruments
Disposable surgical blades
Scalpel handles
Artery forceps
Mosquito forceps
Dissecting forceps
Suture removal scissors
Cutting scissors
Sponge holding forceps
Dressing bowls (stainless steel)
Kidney trays

24.7.15 Diagnostic Equipment

Digital clinical thermometers
Mercury clinical thermometers (where permitted)
Blood pressure apparatus (Sphygmomanometers)
Pulse oximeters
Stethoscopes

24.7.16 Basic Instrument Sets

Minor Surgery / Dressing Set
Toothed forceps (Adson) — 1
Non-toothed / dissecting forceps — 1
Needle holder (small + medium) — 2
Suture scissors (Mayo, straight) — 1
Dissecting scissors (Metzenbaum, curved) — 1
Scalpel handles (No. 3, No. 4) — 2, with blades (No. 10, 11, 15, 22)
Artery forceps (mosquito, curved/straight) — 4 to 6
Artery forceps (Kelly/Spencer Wells, larger) — 2
Tissue forceps (Allis) — 2
Skin hooks — 2
Retractors (small self-retaining, e.g. Weitlaner) — 1 to 2
Sponge holding forceps — 2
Kidney tray, gallipot

24.7.17 Incision & Drainage / Abscess Set

Sinus forceps
Probe (grooved)
Curette (small)

24.7.18 Additional Instruments

Skin stapler + staple remover
Punch biopsy set (if doing skin biopsies)
Electrocautery unit (portable, battery or mains) — for hemostasis
Suction machine with catheters / tips

24.7.19 Consumables

Sterile gloves (multiple sizes)
Drapes (fenestrated + plain)
Gauze pieces, cotton swabs, cotton balls
Antiseptic solutions: Povidone-iodine, Chlorhexidine, spirit
Local anesthetic: Lignocaine 2% (plain + with adrenaline)
Syringes (2ml, 5ml), needles (24G, 26G)
Normal saline (for irrigation)
Steri-strips, adhesive tapes, transparent dressings (Tegaderm/Opsite)
Sterile dressing pads, bandages, crepe bandages
Suction catheters

24.7.20 Suture Materials:

Suture Material	Sizes
Catgut, plain	3-0, 4-0
Catgut, chromic	2-0, 3-0
Vicryl (polyglactin 910)	2-0, 3-0, 4-0
Vicryl Rapide	4-0, 5-0
Monocryl (poliglecaprone)	4-0, 5-0
Silk	2-0, 3-0, 4-0
Nylon (Ethilon/Monosof)	4-0, 5-0, 6-0
Polypropylene (Prolene)	3-0, 4-0

24.7.21 Hospital Linens & General Consumables

Hospital Linens
Disposable bed sheets
Pillow covers
Clinical blankets

24.7.22 Biomedical Waste Management

Yellow biomedical waste bags
Red biomedical waste bags
Black waste bags (where applicable)
Waste bags in various thicknesses and capacities

24.7.23 Bedside & Patient Care Items

Kidney trays
Disposable paper cups
Medicine cups
Emesis bags (vomit bags)
Disposable drinking glasses
Tongue depressors
Disposable feeding cups

DOCUMENTS COMPRISING THE BID:

I. TECHNICAL BID

Sr. No.	Documents
1	Earnest Money Deposit in the form of Demand Draft/Bank Guarantee
2	Bid Securing declaration
3	Bidder Information Form
4	Bid Form – without mentioning price and discount
5	Performance Statement Form
6	Bidders Undertaking
7	Eligibility Certificate, Non-Black Listing and No Relation Certificate
8	Code of Integrity
9	Solvency Certificate from Bank
10	Letter duly signed by the authorized person and stamped addressed to the Director, CSIR-NAL, Bengaluru indicating the local office and name of authorized person and his contact number at Bengaluru [Rural and Urban]
11	Copy of Consolidation License/Certificate in their name or firm directly owned by / belongs to same group of bidder Company/ firm.
12	Copy of ISO 9001 (2005 or later) Quality Management System Certification.
13	Copy of Goods & Services Tax Registration Certificate and PAN
14	Bidder's commercial terms without disclosing any price / discount elements
15	Audited Balance Sheet duly certified the chartered accountant
16	Undertaking on the Letterhead confirming submission of Performance Security
17	Integirty pact on letter head duly signed and stamped
18	Compliance/Deviation Statement

II. PRICE BID

Sr. No.	Documents
1	Price Schedule
2	Bid Form mentioning price and discount

The documents comprising bid should be submitted in the above sequence in orderly manner.

Tender No.: **ANNEXURE-A**

BID SECURITY FORM

Whereas_____
(hereinafter called the tenderer) has submitted their offer dated
_____for the supply
of_____
(hereinafter called the tender) Against the Purchaser's Tender
No._____KNOW ALL MEN by
these presents that WE _____
of _____having our
registered office at_____are bound unto _____(hereinafter
called the "Purchaser")
In the sum of
_____
For which payment will and truly to be made to the said Purchaser, the Bank binds itself, its successors and assigns by these presents. Sealed with the Common Seal of the said Bank this _____day of _____20_____.

THE CONDITIONS OF THIS OBLIGATION ARE:

(1)	If the tenderer withdraws or amends or modifies or impairs or derogates from the Tender in any respect within the period of validity of this tender OR	
(2)	If the tenderer having been notified of the acceptance of his tender by the Purchaser during the period of its validity	
	(a)	If the tenderer fails to furnish the Performance Security for the due Performance of the contract.
	(b)	Fails or refuses to accept/execute the contract.

We undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or both the two conditions, specifying the occurred condition or conditions.

This guarantee will remain in force up to and including 45 days after the period of tender validity and any demand in respect thereof should reach the Bank not later than the above date.

_____
(Signature of the authorized officer of the Bank)

Name and designation of the officer
Seal, name & address of the Bank and address of the Branch

Note: Whenever the bidder chooses to submit the Bid Security in the form of Bank Guarantee, then he should advise the banker issuing the Bank Guarantee to immediately send by Registered Post (A.D.) an unstamped duplicate copy of the Guarantee directly to the Purchaser with a covering letter to compare with the original BG for the correctness, genuineness, etc.

Tender No.: **ANNEXURE-B**

BID-SECURING DECLARATION FORM

Date:_____

Bid No. _____

To (insert complete name and address of the purchaser)

I/We. The undersigned, declare that:

I/We understand that, according to your conditions, bids must be supported by a Bid Securing Declaration.

I/We accept that I/We may be disqualified from bidding for any contract with you for a period of one year from the date of notification, if I am/We are in a breach of any obligation under the bid conditions, because I/We

(a)	have withdrawn/modified/amended, impairs or derogates from the tender, my/our Bid during the period of bid validity specified in the form of Bid; or
(b)	having been notified of the acceptance of our Bid by the purchaser during the period of bid validity. (i) fail or reuse to execute the contract, if required, or (ii) fail or refuse to furnish the Performance Security, in accordance with the Instructions to Bidders.

I/We understand this Bid Securing Declaration shall cease to be valid, if I am/We are not the successful Bidder, upon the earlier of (i) the receipt of your notification of the name of the successful Bidder; or (ii) thirty days after the expiration of the validity of my/our Bid.

Signed: (insert signature of person whose name and capacity are shown) in the capacity of (insert legal capacity of person signing the Bid Securing Declaration).

Name: (insert complete name of person signing he Bid Securing Declaration)

Duly authorised to sign the bid for an on behalf of: (insert complete name of Bidder)

Dated on _____ day of _____(insert date of signing)

Corporate Seal (where appropriate)

(Note: In case of a Joint Venture, the Bid Securing Declaration must be in the name of all partners to the Joint Venture that submits the bid)

Tender No.: **ANNEXURE - C**

Bidder Information Form

(a) [The Bidder shall fill in this Form in accordance with the instructions indicated below. No alterations to its format shall be permitted and no substitutions shall be accepted. This should be done of the letter head of the firm]

Date : ***[insert date (as day, month and year) of Bid Submission*]**

Tender No : ***[insert number from Invitation for bids]***

1	Bidder's Legal Name	
2	In case of JV, legal name of each party	
3	Bidder's actual or intended Country of Registration	
4	Bidder's Year of Registration	
5	Communication Address	
6	Phone No. / Mobile No.	
7	Fax No.	
8	Email ID	

PARTICULAR DETAILS OF THE BIDDER'S REPRESENTATIVE

1	Name of the Contact Person	
2	Designation	
3	Phone No.	
4	Mobile No.	
5	Email ID	
6	Attached copies of original documents of Articles of Incorporation or Registration of firm named in 1, above.	

Signature of Bidder _____

Name _____

Business Address _____

Tender No.: **ANNEXURE-D**

Bid Form

[The Bidder shall fill in this Form in accordance with the instructions indicated No alterations to its format shall be permitted and no substitutions shall be accepted.]

Date **: *[insert date (as day, month and year) of Bid Submission]***
Tender No. :
To : The, Director, *CSIR-NAL, Bengaluru*
We, the undersigned, declare that:

(a)	We have examined and have no reservations to the Bidding Documents, including Addenda issued in accordance with Instructions to Bidders.
(b)	We offer to execute in conformity with the Bidding Documents and in accordance with the Services *as specified in Chapter 3*
(c)	The total price of our Bid, excluding any discounts offered in item (d) below, is: ***[insert the total bid price in words and figures, indicating the various amounts and the respective currencies]***
(d)	The discounts offered and the methodologies for their application are: **Discounts.** If our bid is accepted, the following discounts shall apply. ***[Specify in detail each discount offered and the specific item of the Schedule of Requirements to which it applies.]***
(e)	Our bid shall be valid for the period of time specified in ITB Clause 1.16, from the date fixed for the bid submission due date in accordance with ITB Clause 1.19 and it shall remain binding upon us and may be accepted at any time before the expiration of that period
(f)	If our bid is accepted, we commit to obtain a performance security in accordance with the Bidding documents.
(g)	The following commissions, gratuities, or fees have been paid or are to be paid with respect to the bidding process or execution of the Contract**: *[insert complete name of each Recipient, its full address, the reason for which each commission or gratuity was paid and the amount and currency of each such commission or gratuity]***

Name of Recipient	Address	Reason	Amount

(If none has been paid or is to be paid, indicate “none.”)

(h)	We understand that this bid, together with your written acceptance thereof included in your notification of award, shall constitute a binding contract between us, until a formal contract is prepared and executed.
(i)	We also accept all the terms and conditions of this Bidding Document and undertake to abide by them, including the condition that you are not bound to accept the lowest evaluated bid / highest ranked bid or any other bid that you may receive.
(k)	We also declare that Government of India or any other Government body has not declared us ineligible or black listed us on charges of engaging in corrupt, fraudulent, collusive or coercive practices or any failure/lapses if serious nature.

Signed :
[insert signature of person whose name and capacity are shown]
In the capacity of ***[insert legal capacity of person signing the Bid Submission Form]***

Name**:**
[insert complete name of person signing the Bid Submission Form]

Duly authorized to sign the bid for and on behalf of: ***[insert complete name of Bidder]***
Dated on _____ day of _____, _____ ***[insert date of signing]***

Tender No.: **ANNEXURE-E**

PERFORMANCE STATEMENT FORM

S. N.	Client Details (Name / Address / Phone / Email)	Services Provided	Period / Duration
1			
2			
3.			
4.			
5.			
6.			
7.			
8.			

Note: It is mandatory to attach documentary evidence about satisfactory performance of service issued by at least two clients mentioned above along with **TECHNICAL BID**. Correct and complete contact details must be furnished to enable CSIR-NAL to verify the satisfactory service credentials claimed by the bidder, if required.

Signature and Seal of the Bidder…….

Place:
Date:

Tender No.: **ANNEXURE-F**

(On the Letter Head of the Bidder)

UNDERTAKING BY THE BIDDER

We, **M/s. _____**, having our registered office at **_____**, through our authorised signatory, hereby solemnly undertake and affirm as follows:

1. We undertake to submit the **Performance Security** in the acceptable form and within the stipulated period, as specified in the Tender Document.
2. We agree to accept and comply with the **Liquidated Damages (LD) clause** and other applicable Terms & Conditions stipulated in the Tender Document.
3. We undertake to **establish, operate and maintain the Single Window Pharmacy Management System (SWPMS)** in accordance with the scope of work, technical specifications, service requirements and other terms and conditions specified in the Tender Document.
4. We undertake to ensure **uninterrupted and efficient operation of the pharmacy services**, including supply, storage, dispensing and management of medicines and other items, as applicable under the scope of the Contract.
5. We undertake to maintain all required **records, registers, inventory details, prescriptions, invoices, stock statements and other documents/data** in accordance with the requirements of CSIR-NAL and applicable statutory provisions.
6. We undertake to comply with all applicable **laws, rules, regulations, licences, registrations and statutory requirements** relating to the operation of the pharmacy and supply/dispensing of medicines and other medical items during the entire contract period.
7. We solemnly affirm that **no legal dispute is pending against us with CSIR-NAL**, which would affect our eligibility or ability to perform the obligations under the proposed Contract.
8. We solemnly affirm that our firm/company is **not blacklisted, debarred or banned** by any Government Department/Organisation, CSIR Laboratory/Institute or other client organisation, as on the date of submission of the bid.
9. We undertake that we shall **not engage in or associate ourselves with any corrupt, fraudulent, coercive, collusive or unethical practices** while participating in the tender process or while performing our obligations under the Contract.
10. We affirm that all **information, documents, declarations and statements furnished by us in the Bid are true, complete and correct** to the best of our knowledge and belief. We understand that any false, incorrect or misleading information may result in rejection of our bid and/or such action as may be permissible under the Tender Document and applicable rules.
11. We hereby **unconditionally accept all the terms and conditions, specifications, scope of work and requirements** stipulated in the Tender Document and undertake to comply with the same in the event of award of the Contract.
12. We undertake that, in the event of award of the Contract, we shall **faithfully perform all contractual obligations** and provide the services in accordance with the requirements of CSIR-NAL throughout the contract period.

We hereby confirm that the above undertaking is given in good faith and shall be binding on our firm/company.

For and on behalf of M/s. _____
Name of Authorised Signatory: _____
Designation: _____
Signature: _____
Date: _____
Place: _____
Seal of the Bidder

Tender No.: **ANNEXURE-G**

Eligibility Declaration

This is to certify that we are not associated, or have been associated in the past, directly or indirectly, with a firm or any of its affiliates which have been engaged by the Purchaser to provide Services under this Invitation of Bids

Non-Black listing Declaration

This is to certify that our firm has not been blacklisted by any Central / State Government Department / Organization in last 3 years.

No Relation Declaration

I..... son of ..... resident of ..... hereby certify that none of my relative(s) is / are employed in CSIR-National Aerospace Laboratories, Bengaluru. In case at any stage, it is found that the information given by me is false / incorrect, CSIR-NAL shall have the absolute right to take any action as deemed fit / without any prior intimation to me.

Signed.....

For and on behalf of the Bidder

Name .....

Designation .....

Date.....

Tender No.: **ANNEXURE–H**

FORMAT OF INTEGRITY PACT

Between

Council of Scientific & Industrial Research (CSIR) a Society registered under the Indian Societies Act 1860 represented by _____ hereinafter referred to as "The Principal".

And ……herein referred to as "The Bidder/ Contractor".

Preamble

The Principal intends to award, under laid down organisational procedures, contract(s) for……The Principal values full compliance with all relevant laws of the land, rules, regulations, economic use of resources and of fairness/transparency in its relations with its Bidder(s) and/or Contractor(s).

In order to achieve these goals, the Principal will appoint an Independent External Monitor (IEM), who will monitor the tender process and the execution of the contract for compliance with the principles mentioned above.

Section: 1 – Commitments of the Principal

(1) The Principal commits itself to take all measures necessary to prevent corruption and to observe the following principles:
No employee of the Principal, personally or through family members, will in connection with the tender for, or the execution of a contract, demand, take a promise for or accept, for self or third person, any material or immaterial benefit which the person is not legally entitled to.
The Principal will, during the tendering process treat all Bidder(s) with equity and reason.
The Principal will in particular, before and during the tendering process, provide to all Bidder(s) the same information and will not provide to any Bidder(s) confidential/additional information through which the Bidder(s) could obtain an advantage in relation to the tendering process or the contract execution.
The Principal will exclude from the process all known prejudiced person(s).

(2) If the Principal obtains information on the conduct of any of its employees which is a criminal offence under the IPC/PC Act, or if there be a substantive suspicion in this regard, the Principal will inform the Chief Vigilance Officer and in addition can initiate disciplinary action.

Section: 2 – Commitments of the Bidder(s)/Contractor(s)

(1) The Bidder(s)/Contractor(s) commit himself to take all measures necessary to prevent corruption. He commits himself to observe the following principles during his participation in the tendering process and while executing the contract.

The Bidder(s)/Contractor(s) will not, directly or through any other Person or firm, offer, promise or give to any of the Principal's employees involved in the tendering process or the execution of the contract or to any third person any material or other benefit which he/she is not legally entitled to, in order to obtain in exchange any advantage of any kind whatsoever during the tendering process or while executing the contract.
The Bidder(s)/Contractor(s) will not enter with other Bidders' into any undisclosed agreement or understanding, whether formal or informal. This applies in particular to prices, specifications, certifications, subsidiary contracts, submission or non-submission of bids or any other actions to restrict competitiveness or to introduce cartelisation in the bidding process.

The Bidder(s)/Contractor(s) will not commit any offence under the relevant IPC/PC Act; further the Bidder(s)/Contractor(s) will not use improperly, for purposes of competition or personal gain, or pass on to others, any information or document provided by the Principal as part of the business relationship, regarding plans, technical proposals and business details, including information contained or transmitted electronically.

The Bidder(s)/Contractor(s) of foreign origin shall disclose the name and address of the Agents/representatives in India, if any. Similarly the Bidder(s)/Contractors(s) of Indian nationality shall furnish the name and address of the foreign principals, if any. Further, details as mentioned in the "Guidelines on Indian Agents of Foreign Suppliers", shall be disclosed by the Bidder(s)/Contractor(s). Further, as mentioned in the Guidelines all the payments made to the Indian agent/representative have to be in Indian Rupees only. Copy of the "Guidelines on Indian Agents of Foreign Suppliers", is annexed and marked as Annexure.

The Bidder(s)/Contractor(s) will, when presenting his bid, disclose any and all payments he has made, is committed to or intends to make to agents, brokers or any other intermediaries in connection with the award of the contract.

The Bidder(s)/Contractor(s) will not instigate third person(s) to commit offences outlined above or be an accessory to such offences.

The person signing IP shall not approach the courts while representing the matters to IEMs and he/she will await their decision in the matter.

Section: 3 – Disqualification from tender process and exclusion from future Contracts

(1) If the Bidder(s)/Contractor(s), before award or during execution has committed a transgression through a violation of Section - 2, above or in any other form such as to put his reliability or credibility in question, the Principal is entitled to disqualify the Bidder(s)/Contractor(s) from the tendering process or take action as per the procedure mentioned in the "Guidelines on Banning of Business Dealings". Copy of the "Guidelines on Banning of Business Dealings".

Section: 4 – Compensation for Damages

(1) If the Principal has disqualified the Bidder(s) from the tender process prior to the award according to Section - 3, the Principal is entitled to demand and recover the damages equivalent to the Earnest Money Deposit/Bid Security.

(2) If the Principal has terminated the contract according to Section - 3, or if the Principal is entitled to terminate the contract according to Section - 3, the Principal shall be entitled to demand and recover from the Contractor Liquidated Damages of the contract value or the amount equivalent to Performance Bank Guarantee.

Section: 5 – Previous transgression

(1) The Bidder declares that no previous transgressions occurred in the last 3 (three) years with any other Company in any country conforming to the anti-corruption approach or with any other Public Sector Enterprise in India that could justify his exclusion from the tender process.

(2) If the Bidder makes incorrect statement on this subject, he can be disqualified from the tendering process or action can be taken as per the procedure mentioned in "Guidelines on Banning of Business Dealings".

Section: 6 – Equal treatment of all Bidders/Contractors/Sub-contractors

(1) The Bidder(s)/Contractor(s) undertake(s) to demand from all Sub-contractors a commitment in conformity with this Integrity Pact, and to submit it to the Principal before the signing of the contract.

(2) The Principal will enter into agreements with identical conditions as this one with all Bidders', Contractors' and Subcontractors'.

(3) The Principal will disqualify from the tendering process all bidders' who do not sign this Pact or violate its provisions.

Section: 7 – Criminal charges against violating Bidders/Contractors/Sub-contractors.

(1) If the Principal obtains knowledge of conduct of a bidder, Contractor or Sub-contractor or of an employee or a representative or an associate of a bidder, Contractor or Sub-contractor which constitutes corruption, or if the Principal has substantive suspicion in this regard, the Principal will inform the same to the Chief Vigilance Officer. Section: 8 - Independent External Monitors

Section 8 - Independent External Monitors

(1) The Principal appoints competent and credible Independent External Monitor for this Pact. The task of the Monitor is to review independently and objectively, whether and to what extent the parties comply with the obligations under this agreement.

(2) The Monitor is not subject to instructions by the representatives of the parties and performs his functions neutrally and independently. He reports to the JS (A), CSIR.

(3) The Bidder(s)/Contractor(s) accepts that the Monitor has the right to access without restriction to all Project documentation of the Principal including that provided by the Contractor. The Contractor will also grant the Monitor, upon his request and demonstration of a valid interest, unrestricted and unconditional access to his project documentation. The same is applicable to Subcontractors. The Monitor is under contractual obligation to treat the information and documents of the Bidder(s)/ Contractor(s) / Subcontractor(s) with confidentiality.

(4) The Principal will provide to the Monitor sufficient information about all meetings among the parties related to the Project provided such meetings could have an impact on the contractual relations between the Principal and the Contractor. The parties offer to the Monitor the option to participate in such meetings.

(5) As soon as the Monitor notice, or believes to notice, a violation of this agreement, he will so inform the Management of the Principal and request the Management to discontinue or take corrective action, or to take other relevant action. The monitor can in this regard submit non-binding recommendations. Beyond this, the Monitor has no right to demand from the parties that they act in a specific manner, refrain from action or tolerate action.

(6) The Monitor will submit a written report to the JS(A), CSIR within 8 to 10 weeks from the date of reference or intimation to him by the Principal and should the occasion arise, submit proposals for correcting problematic situations.

(7) Monitor shall be entitled to compensation on the same terms as being extended to/provided to Independent Directors on the CSIR.

(8) If the Monitor has reported to the JS(A), CSIR, a substantiated suspicion of an offence under relevant IPC/PC Act, and the JS(A), CSIR has not, within the reasonable time taken visible action to proceed against such offence or reported it to the Chief Vigilance Officer, the Monitor may also transmit this information directly to the Central Vigilance Commissioner.

(9) The word 'Monitor' would include both singular and plural.

Section 9 – Pact Duration

(1) This Pact begins when both parties have legally singed it. It expires for the Contractor 10 (ten) months after the last payment under the contract, and for all other Bidders 6 (six) months after the contract has been awarded.

(2) If any claim is made/lodged during this time, the same shall be binding and continue to be valid despite the lapse of this pact as specified above, unless it is discharged/determined by JS(A), CSIR.

Section 10 – Other provisions

(1) This agreement is subject to Indian Law. Place of performance and Jurisdiction is the Registered Office of the Principal, i.e., New Delhi.

(2) Changes and supplements as well as termination notices need to be made in writing. Side agreements have not been made.

(3) If the Contractor is a partnership or a consortium, this agreement must be signed by all partners or consortium members.

(4) Should one or several provisions of this agreement turn out to be invalid, the remainder of this agreement remains valid. In this case, the parties will strive to come to an agreement to their original intentions.

_____	_____
(For & On behalf of the Principal)	(For & On behalf of Bidder/Contractor)
(Office Seal)	(Office Seal)
Place……	Place……
Date……..	Date……..

Witness
1: (Name & Address): _____

Witness
2: (Name & Address): _____

Tender No.: **ANNEXURE-I**

Addresses & Contact Details of Offices in Bengaluru [Rural and Urban]

Sr. No.	Address	Contact Details (Name / Telephone / email etc.)	Whether registered?

Signature and Seal of the Bidder…….

Place :

Date :

Tender No.:

ANNEXURE - J

COMPLIANCE / DEVIATION STATEMENT FORM

(ITB, TERMS & CONDITIONS, SERVICE & QUALIFICATION REQUIREMENTS)

Following is the compliance / deviation on the Purchaser's Service Requirement as per T&C, Service Specifications, and Qualification Requirements demonstrating substantial responsiveness of the bidder's willingness to meet those requirements to the provisions of the tender document.

S. No.	Tender T&C and Specifications	Bidder's Specifications	Remarks/Deviation If any

(PLESE ATTACH NECESSARY CERTIFICATES / DOCUMENTS / UNDERTAKING ETC. WHEREEVER REQUIRED)

Signature and Seal of the Bidder……

Place :

Date :

Tender No.:

Annexure –K

Price Schedule Form

The Bidder may fill the BoQ / Price Schedule Form as per the format below in the CPP Portal. Column No.13, to be entered as numeral only. (eg. It should be entered as 3 and not as 3%)

Sl. No.	Item Description	Item Code / Make	% of Discount offered
1	2	3	13
1	Essential Primary Care & General Therapeutics	CATEGORY 1 (C1)	
2	Life-Saving & Emergency Medications	CATEGORY 2 (C2)	
3	Vaccines & Immunological Biologics	CATEGORY 3 (C3)	
4	Controlled Substances & Narcotics	CATEGORY 4 (C4)	
5	Specialized Antineoplastics & Immunosuppressives	CATEGORY 5 (C5)	
6	Diagnostic Reagents & Laboratory Equipment Consumables	CATEGORY 6 (C6)	
7	Surgical and Medical Cosumables (Nursing station)	CATEGORY 7 (C7)	

Note:

01. The discount should be firm and fixed and should be applicable uniformly.
02. **Award Criteria:** The contract will be awarded to the lowest evaluated responsive bidder i.e. one who offers the maximum discount**.** The bidder shall offer the discount applicable to, or ordinarily provided to, Government hospitals, institutions, and other Government organizations.
03. The contract shall be awarded in its entirety to one qualified and responsive bidder.

    No category-wise or partial award shall be made.

    In the event of a tie in the Combined Tender Score, preference shall be given to the bidder securing the higher **Technical Evaluation Score (TES)**.

Signature of the authorized person of the Bidder :……

Name of the authorized person :……

Rubber Stamp / Seal

Detailed category and respective sub-categories as per Clause No.24.0

Category	Details	% of Discount offered
CATEGORY 1 (C1)	**Essential Primary Care & General Therapeutics**	
	Anti-infectives	
	Cardiovascular Medicines	
	Endocrine & Metabolic Medicines	
	Gastrointestinal Medicines	
	Respiratory Medicines	
	Central Nervous System Medicines	
	Pain & Inflammation	
	Dermatological Preparations	
	Ophthalmic Preparations	
	ENT Preparations	
	Dental Preparations	
	Obstetrics & Gynaecology Medicines	
	Urology & Nephrology Medicines	
	Paediatric Medicines	
	Geriatric Medicines	
	Vitamins, Minerals & Nutrition	
	Blood & Hematological Medicines	
	Intravenous Fluids & Electrolytes	
	Diagnostic Agents	
	Miscellaneous Therapeutics	
CATEGORY 2 (C2)	**Life-Saving & Emergency Medications**	
	Emergency Cardiovascular Medicines	
	Emergency Respiratory Medicines	
	Emergency Allergy & Anaphylaxis	
	Emergency Neurology	
	Emergency Anaesthesia	
	Emergency Fluids & Electrolytes	
	Emergency Toxicology	
	Emergency Toxicology	
	Emergency Obstetrics	
	Emergency Gastrointestinal	
	Emergency Infectious Diseases	
	Emergency Endocrine	
	Emergency Blood Products	
	Intensive Care Medicines	
	Miscellaneous Emergency Medicines	
CATEGORY 3 (C3)	**Vaccines & Immunological Biologics**	
	Bacterial Vaccines	
	Viral Vaccines	
	Combination Vaccines	
	National Immunization Programme Vaccines	
	Travel Vaccines	

	Occupational Vaccines	
	Immunoglobulins	
	Antisera	
	Antitoxins	
	Monoclonal Antibodies	
	Blood-Derived Biological Products	
	Allergy Immunotherapy	
	Diagnostic Immunobiologicals	
	Cold Chain Biologicals	
	Emergency Biologicals	
	Miscellaneous Immunological Products	
CATEGORY 4 (C4)	**Controlled Substances & Narcotics**	
	Opioid Analgesics	
	Narcotic Analgesics	
	Sedatives & Hypnotics	
	Psychotropic Medicines	
	Anaesthetic Agents	
	Muscle Relaxants	
	Controlled Anticonvulsants	
	Schedule X Medicines	
	Schedule H1 Medicines	
	Schedule H1 Medicines	
	NDPS Medicines	
	NDPS Medicines	
	Controlled Emergency Medicines	
	Controlled Oncology Medicines	
	Controlled Palliative Care Medicines	
	Controlled Obstetric Medicines	
	Controlled Veterinary Narcotics	
	Regulatory & Compliance Medicines	
CATEGORY 5 (C5)	**Specialized Antineoplastics & Immunosuppressives**	
	Cytotoxic Chemotherapy	
	Targeted Therapy	
	Immunotherapy	
	Hormonal Anticancer Therapy	
	Immunosuppressive Medicines	
	Disease-Modifying Medicines	
	Supportive Oncology	
	Cellular & Gene Therapy	
	Miscellaneous Oncology Products	
CATEGORY 6 (C6)	**Diagnostic Reagents & Laboratory Equipment Consumables**	
	Clinical Biochemistry Reagents (COBAS C111 Analyser)	
	Hematology Reagents (Sysmex)	
	Microbiology Reagents	
	Laboratory Chemicals	
	Instrument Consumables	

	Point-of-Care Testing (POCT)	
	Laboratory Safety Consumables	
	Miscellaneous Laboratory Products	
CATEGORY 7 (C7)	**Surgical and Medical Cosumables (Nursing station)**	
	Consumables & Dressings	
	Tapes	
	Swabs & Cotton	
	Nebulization & Oxygen Supplies	
	Personal Protective Equipment (PPE) & Infection Control	
	Masks & Headwear	
	Gowns & Drapes	
	Hygiene & Disinfection	
	Syringes, Needles & IV Administration	
	Hypodermic Needles	
	IV Administration	
	IV Cannulas	
	Catheters & Drainage	
	Surgical & Diagnostic Instruments	
	Diagnostic Equipment	
	Basic Instrument Sets	
	Incision & Drainage / Abscess Set	
	Additional Instruments	
	Consumables	
	Suture Materials	
	Hospital Linens & General Consumables	
	Biomedical Waste Management	
	Bedside & Patient Care Items	